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SUMMARY 
Hepatitis E virus (HEV) is an important cause of enterically transmitted acute hepatitis 
worldwide and is a locally acquired disease in both developing and developed nations. Different 
genotypes in these two regions display the different characteristics of this interesting infection. 
HEV is classified into four major genotypes and it can present as two contrasting clinical 
entities. HEV genotypes 1 (HEV1) and 2 (HEV 2) are related to waterborne transmission and 
poor sanitation. Whereas genotypes 3 (HEV3) and 4 (HEV4) are associated with zoonotic 
transmission mainly through pigs, wild boar and deer. HEV infections in Africa are thought to be 
caused by HEV1 and HEV2. The seroprevalence of HEV has been described in Southern 
Africa, but all more than 10 years ago when assays were not well developed. South Africa has 
three HEV reports, describing a hospital outbreak, and the seroprevalence in specific 
communities of South Africa. The seroprevalence from these studies ranged from 2% to 10.7% 
however no genotyping was done. 
Researchers have reported evidence of direct and indirect transfusion-transmitted HEV infection 
being a potential risk to recipients of blood transfusions. Asymptomatic HEV infections in blood 
donors increase the likelihood that blood or blood products are contaminated with HEV viral 
particles. Hence, there is a greater chance of infecting high-risk recipient groups with 
compromised immune systems. Therefore, the main aim of this study was to determine the 
prevalence of past and active HEV infection in blood donors from the Western Cape. We also 
investigated which risk factors are associated with infection. 
Our study population consisted of 10,250 blood donors that were tested as two sub-studies. For 
study group 1 we recruited 250 donors to complete an HEV risk questionnaire. Thereafter these 
donors were tested using an indirect Wantai ELISA (Fortress Diagnostics) for anti-HEV IgG 
detection. Statistical analysis was done to determine which demographics and risk factors were 
associated with past HEV infection. In addition, to this, their plasma donations were pooled, 
prior to extraction and amplified with an in-house real-time reverse-transcriptase quantitative 
polymerase chain reaction (RT-qPCR) to detect HEV RNA. The 10,000 blood donors of study 
group 2 were tested as individual donations using a commercial Procleix HEV nucleic acid 
testing (NAT) assay to qualitatively detect HEV RNA by transcription-mediated amplification 
(TMA). Thereafter repeat-reactive donations were quantified using our in-house real-time RT-
qPCR. 
The total anti-HEV IgG seroprevalence of our study was found to be 42.4% in blood donors 
(study group 1). Risk analysis revealed that eating turkey (p=0.001) and organ meat (p=0.026) 
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and canoeing (p=0.017) were significantly associated with past HEV infection. Whereas direct 
contact with rabbits (p=0.045) or chickens (p=0.020) were statistically significantly different 
means of HEV exposure associated with HEV3 and HEV4. Furthermore, we found that the total 
HEV RNA prevalence was 0.009% (1/10,250). Studies are needed to further assess the risk of 
HEV blood-borne transmission and to understand the epidemiology of HEV in our setting.  
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OPSOMMING 
Hepatitis E virus (HEV) is een van die grootste oorsake van akute hepatitis wêreldwyd en is 
algemeen bekend as 'n plaaslike siekte in baie ontwikkelende lande. Maar HEV infeksie wat 
oorgedra word in ontwikkelde lande word nie net meer verbind met reise na ander lande waar 
HEV infeksie dikwels voorkom nie. HEV word geklassifiseer in vier hoof genotipes en dit kom 
voor as twee kontrasterende kliniese entiteite. HEV genotipes 1 (HEV1) en (HEV 2) is verwant 
aan water oordrag  en swak sanitasie, terwyl genotipes 3 (HEV3) en 4 (HEV4) geassosieer 
word met soönotiese oordrag wat hoofsaaklik plaasvind deur varke, wilde varke en takbokke. 
HEV infeksies in Afrika is vermoedelik veroorsaak deur HEV1 en HEV2. Verskeie gevalle is 
beskryf in Suider-Afrika, maar dit was reeds meer as 10 jaar gelede, toe toetse nog nie goed 
ontwikkel was nie. Suid-Afrika het drie HEV uitbrake gerapporteer; 'n hospitaal uitbraak, en twee 
serologiese voorkoms verslae in spesifieke gemeenskappe van Suid-Afrika. Die serologiese 
voorkoms van hierdie studies het gewissel vanaf 2% tot 10,7% en geen genotipering was 
gedoen nie.  
Navorsers het bewys dat direkte en indirekte-bloedoortapping oordraagbare infeksie van HEV 
moontlik is en 'n potensiële risiko vir ontvangers van bloedoortappings beskryf. Asimptomatiese 
HEV infeksies in bloed skenkers verhoog die waarskynlikheid dat die bloed of bloed produkte 
geïnfekteer is met HEV virale partikels. As gevolg daarvan is daar 'n groter kans dat hoë-risiko 
ontvanger groepe met verswakte immuunstelsels geïnfekteer mag word. Daarom was die 
hoofdoel van hierdie studie om die voorkoms van vorige en aktiewe HEV infeksie in bloed 
skenkers van die Wes-Kaap te bepaal. Ons het ook ondersoek watter risiko faktore verband hou 
met infeksie. 
Ons studie het bestaan uit 10,250 bloed skenkers wat getoets was as deel van twee sub-
studies. Vir studie groep 1 het ons 250 skenkers gewerf om 'n HEV risiko vraelys te voltooi. 
Hierdie skenkers was getoets met behulp van 'n indirekte Wantai toets (Fortress Diagnostics) vir 
die identifisering van anti-HEV IgG. Daarna was statistiese analise gedoen om te bepaal wat die 
demografie en risiko faktore is wat verband hou met die voorkoms van vorige HEV infeksie. 
Benewens hierdie was hul plasma monsters saamgevoeg, voor ekstraksie en amplifikasie met 
'n in-huis intydse omgekeerde transkriptase-kwantitatiewe polimerase kettingreaksie (PKR) om 
HEV RNS te spoor. Die 10,000 bloed skenkers van studie groep 2 was getoets as individuele 
skenkings met die gebruik van 'n kommersiële Procleix HEV NST toets om HEV RNS deur 
transkripsie amplifikasie te kwantifiseer. Daarna is herhaalde reaktiewe skenkings 
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gekwantifiseer met behulp van ons in-huis intydse omgekeerde transkriptase-kwantitatiewe 
PKR. 
Die totale serologiese voorkoms van antiliggame teen HEV vir ons studie was 42,4% in 
bloedskenkers (studie groep 1). Risiko analise het aan die lig gebring dat om kalkoen (p=0.001) 
en orgaan vleis te eet (p=0.026) wat aanleiding gee tot ‘n voedselverwante oordrag van HEV3, 
en kanovaart (p=0.017) wat deur middel van water lei tot oordrag van HEV1, hou beduidend 
verband met die voorkoms van vorige HEV infeksie. Direkte kontak met hase (p=0.045) of 
hoenders (p=0.020) was beduidend statisties ‘n metode van HEV blootstelling wat verband hou 
met HEV3 of HEV4. Verder het ons gevind dat die totale HEV RNS voorkoms vir ons studie 
0,009% (1/10,250) was. Studies is nodig om die risiko van HEV stygende oordrag verder te 
evalueer en om die epidemiologie in ons omgewing te verstaan. 
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CHAPTER ONE: INTRODUCTION 
1.1 Background  
Hepatitis E virus (HEV) was first detected in the 1980s when a mysterious hepatitis outbreak 
occurred in Afghanistan at a military camp. The virus was identified in the stool of infected 
individuals by electron microscopy and was later, sequenced and designated as HEV. HEV 
is a hepatotropic virus, which has significantly impacted the health of individuals due to its 
potential to cause acute viral hepatitis (Kamar et al., 2012). According to the global burden of 
diseases (GBD) study which was conducted in 2010, approximately 20.1 million individuals 
were infected with HEV throughout the nine GBD regions during 2005. Of the 20.1 million 
HEV cases, it was reported that 3.4 million were symptomatic infections; 3,000 stillbirths in 
pregnant women and an overall 70,000 of these cases resulted in death (Kumar et al., 
2013).  
1.1.1 HEV: The virus     
HEV is a non-enveloped, positive-sense single-stranded RNA virus which is 32nm to 34nm 
in diameter. It is a member of the Hepeviridae family with several mammalian HEV species 
which infect humans, domestic pigs, deer, wild boar, etc. In addition to this, the Hepeviridae 
family also contains avian HEV and cut-throat trout virus, which is representative of a novel 
genus that has not been linked to human infections (Kamar et al., 2012). The virus was 
initially part of the Caliciviridae family but was reclassified because its genome organization. 
The HEV genome consists of three open reading frames (ORF) that overlap each other. 
ORF1 encodes approximately 1,690 amino acids of a polyprotein which goes through post-
translational cleavage into non-structural proteins required for virus replication. ORF2 is 
responsible for encoding the main structural protein and the capsid protein made up of 660 
amino acids. There is speculation that ORF3 is involved with virus particle assembly 
because it encodes a phosphoprotein that has an association with the cytoskeleton. In the 
different HEV genotypes, ORF3 has a slight variation in its organization, but it retains the 
same functions (Teshale & Hu, 2011). 
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Figure 1.1 Structure of the HEV genome (Kumar et al., 2013 with permission from 
Elsevier) 
 
There are 4 HEV genotypes, 24 sub-types and 1 serotype (Teshale & Hu, 2011). Genotype 
1 (HEV1) is prevalent in Asia and Africa, genotype 4 (HEV4) in Asia and genotype 2 (HEV2) 
in Mexico and West Africa whereas genotype 3 (HEV3) has mostly been reported in 
European countries. HEV1 and HEV2 are associated with large epidemics as well as 
endemics in areas where sporadic cases of hepatitis E occur. HEV3 and HEV4 have been 
detected in humans and in animals. It is thought that it is transmitted by consumption of 
undercooked meat from the infected animals (Teshale et al., 2010a) such as wild boar, deer, 
and pigs (Vollmer et al., 2012). 
 
 
Figure 1.2 Phylogenetic tree of HEV strains isolated from humans and animals (Krain 
et al., 2014 with permission from American Society for Microbiology) 
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1.1.2 Transmission of HEV 
 
HEV has four known modes of transmission; waterborne, zoonotic foodborne, blood-borne 
and perinatal.  
 
1.1.2.1 Waterborne  
 
Waterborne transmission is the major cause of outbreaks in developing countries. HEV is 
spread by drinking water which has been contaminated in the course of waterborne 
epidemics which occasionally occur in tropical and subtropical regions. An investigation took 
place in Somalia and confirmed that HEV infection was waterborne due to a rise in the river’s 
water level during the rainfall season. Consequently, the villagers that acquired their water 
from the river were at risk of being infected with contaminated water. However, the villagers 
getting water from wells displayed very severe cases which resulted in higher fatality rates. It 
was concluded that this inconsistency is an indication of the quantity of HEV required to 
induce the infection (Mushahwar, 2008). 
 
1.1.2.2 Zoonotic foodborne 
 
The zoonotic foodborne transmission of HEV has been reported to be widespread. The 
discovery of swine HEV has led to several studies investigating the homology of human and 
pig strains to determine whether a cross-species infection is possible. For the latter to be 
possible pigs would be a reservoir of the virus and humans would be infected by having 
direct contact with pigs. In addition to this, the consumption of undercooked pig livers has 
resulted in cases of hepatitis E with fatal outcomes reported in older or immunosuppressed 
individuals (Kato et al., 2004). Pig liver and other pig-derived food products have been 
reported to have detectable HEV at different stages in the pork production chain (Di Bartolo 
et al., 2012). Infected wild boar and deer are also known to cause zoonotic foodborne 
transmission of HEV. However unlike domestic pigs that usually live on farms, wild animals 
inhabit forest regions and could be exposed to various environmental sources of HEV 
(Lagler et al., 2014). The faecal-oral route may be associated with HEV infection in animals 
via faecal contaminated water or food sources and is probably due to defecation from an 
infected animal within the forest (Mushahwar, 2008). The latter suggests that the virus can 
be easily transmitted between a source and reservoir. Furthermore amongst other studies 
Takahashi et al. have shown that wild boar and deer have intra-species transmission of HEV 
and that humans have become infected by eating raw or undercooked contaminated meat 
from these species (Takahashi et al., 2004).  
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Wibawa et al., 2004 investigated the seroprevalence of HEV in Bali Indonesia in both pigs 
72% (71/99) and blood donors 20% (54/276) and later in pregnant women with different 
dietary habits due to religious restrictions (Surya et al., 2005). They found that more than 
50% of the pigs sampled in Bali had evidence of HEV exposure (Wibawa et al., 2004) hence 
possibly being a means of exposure to the majority of their Hindu residents. Residents who 
have pigs in their households are in direct contact with pigs i.e. through their faeces. Surya 
et al. compared the difference in HEV IgG seroprevalence of Hindu pregnant women (19%) 
with that of Muslim pregnant women (4%). They found that religious restrictions on eating 
pork may have influenced the lower prevalence in Muslim women; in that 2 of 50 were anti-
HEV IgG positive. Whereas 149 of 749 of the Hindu women not prohibited to eating pork 
were seropositive (Surya et al., 2005).  
 
1.1.2.3 Blood-borne 
 
Transmitting HEV via blood products is a known risk however the prevalence of HEV 
transfusion-transmitted infection (TTI) varies and has limited data. In Spain a prevalence 
study was done among blood donors from Catalonia, Barcelona to investigate the safety of 
blood donations by screening 9,998 individual samples for HEV RNA. The assay which they 
used for nucleic acid testing (NAT) had a detection limit of 7.9 IU/ml (95% fiducial limits, 6.6-
9.8 IU/ml) which was able to identify 3 HEV RNA positive individual donations with viral 
loads of 250, 564 and 2,755 IU/ml. Sequencing could only be done for the blood donor with 
the highest viral load and the HEV genotype was found to be 3f. The blood donors in 
Catalonia have a background HEV prevalence of 0.03% which is equivalent to approximately 
1 in every 3,333 blood donations being viraemic. Hence, 25 to 225 of their annual 250,000 
regional blood donations would be at risk of transmitting HEV. In addition to this depending 
on the presence of HEV antibodies in the blood donors, the amount of viral load and the 
remaining plasma present in their blood donation it could influence the transmission of the 
virus (Sauleda et al., 2015). Hence, it is difficult to establish when recipients will be infected 
with HEV contaminated blood products. 
 
1.1.2.4 Perinatal 
 
Pregnant women in developing countries have been greatly affected by HEV1 and HEV2 
epidemics. The factors thought to be associated with an increased risk of mortality are 
altered immune response, hormonal changes associated with pregnancy and malnutrition 
(Kumara et al., 2004). The severity of maternal deaths caused by HEV infection occurs 
during the third trimester of pregnancy (Labrique et al., 2012). 
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1.1.2.5 Possible HEV transmission routes and genotypes expected in South Africa 
 
HEV1 and HEV2 are expected to be prevalent in South Africa due to the geographical 
distribution of HEV (Figure 2.1). Most developing African countries have tropical climate 
conditions and seasonal rain that cause waterborne outbreaks which favour the faecal-oral 
transmission of HEV. Without proper housing, sanitation and safe drinking water, many 
individuals living in rural areas are easily exposed to enteric viruses such as HEV. However, 
faecal-oral transmission associated with HEV1 and HEV2 may not be the only cause of 
hepatitis E cases in developing countries. Several cases of HEV have been reported in 
South Africa (MI. Andersson personal communication, 2015) and suggest that the 
epidemiology of HEV in South Africa has changed. 
 
A travel-associated case of HEV1 was diagnosed in a patient after returning from Pakistan 
(Andersson et al., unpublished data). The latter case is almost similar to the hepatitis E 
diagnosis made a few years ago that was reported to be an imported infection from India, 
but no genotyping was done due to limited HEV tests available at the time (Robson et al., 
1992). However it was recommended by Robson et al. that hepatitis E should be suspected 
in individuals traveling to the Indian subcontinent, which was found in the patients returning 
from Pakistan (Andersson et al., 2015) and India (Robson et al., 1992).  
 
In 2012, the production of South African meat products was under investigation for 
substituting animal species and incorrect labelling or omitting to label animal species that 
were present in meat products. The Department of Animal Sciences (University of 
Stellenbosch) and the Food & Allergy Consulting & Testing Services worked in collaboration 
to assess the processing and labelling of 139 meat products. These products were bought 
from retailers in the most populated provinces of South Africa; 38 from Western Cape, 28 
from Eastern Cape, 38 from KwaZulu-Natal and 35 from Gauteng (Cawthorn et al., 2013). 
The abovementioned study revealed that there is indeed meat contamination which 
suggests that foodborne zoonotic transmission associated with HEV3 may occur through 
contaminated meat products sold in South Africa.  
 
One of the HEV cases from South Africa involved an immunosuppressed HIV-infected 
patient from Cape Town that was diagnosed with chronic HEV infection (Andersson et al., 
2012) which is associated with HEV3 (Kamar et al., 2012). The latter patients’ phylogenetic 
analysis revealed HEV3 clustering and the patient cleared the virus infection when he was 
started on antiretroviral drugs (ARVs) (Andersson et al., 2012). Recently another case of 
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HEV3 was reported in a patient that received a renal transplant at a hospital in Cape Town 
(Andersson et al., 2015). The above-mentioned reports show that HEV3 seems to be 
prevalent in South Africa.  
 
 
 
Figure 1.3 HEV routes of transmission (Kamar et al., 2012 with permission from Elsevier) 
 
1.1.3 Clinical presentation and natural history 
The clinical presentation of HEV is comparable to other hepatotropic viruses which also 
induce acute viral hepatitis infections. Individuals infected with HEV display a broad range of 
clinical features ranging from fulminant to asymptomatic infections. The features are 
jaundice, anorexia, malaise, fever, pruritus and hepatomegaly. The laboratory results 
associated with these symptoms are increased levels of bilirubin in the serum, noticeable 
elevation of alanine transaminase (ALT) and aspartate transaminase (AST) and a slight 
increase in the alkaline phosphatase activity (Teshale et al., 2010a).  
Hepatitis E is generally self-limiting, but it may potentially develop into the fulminant disease 
(Vollmer et al., 2012). HEV has an incubation period of 2 to 6 weeks. HEV infection is 
represented by an initial temporary HEV IgM response which is followed by a long-lasting 
HEV IgG response. Acute HEV infection displays a peak in HEV RNA during the incubation 
period and the early phases of HEV infection. After infected individuals start developing 
symptoms the HEV RNA in the blood becomes undetectable although it can still be detected 
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in faeces for further 10-14 days. The window period for detecting HEV RNA is thus narrow 
(Kamar et al., 2012). 
1.1.4 Diagnosis of HEV 
Acute HEV infection is diagnosed by detecting IgM or the seroconversion from IgG negative 
to positive using a serology based enzyme immunoassay (EIA). Anti-HEV IgM is detected 
first and anti-HEV IgG is detected shortly after the IgM response. Antibodies (IgM and IgG) 
produced against HEV are diagnostic markers that help to determine the stage of infection 
(Isaäcson et al., 2000), which could be either a recent or past infection. However serological 
kits use different antigens that are coated to the wells of the ELISA plate which has an 
influence on the sensitivity and specificity of the assay. Alternatively molecular testing is 
essential to detect replicating virus RNA, suggesting an active infection. Nucleic acid tests 
such as a polymerase chain reaction (PCR) assay detects HEV RNA in the blood and stool 
samples indicating the presence of the virus i.e. current infection. Detection of HEV RNA is 
possible earlier in blood than in stool samples (Teshale et al., 2010a).  
Chronic HEV infection is defined by persistent HEV RNA in the serum or stool samples, for 
at least six months. Chronic HEV has been described in patients that received solid organ 
transplants, in HIV patients and those with haematological malignancies such as B-cell 
chronic lymphocytic leukaemia (Gauss et al., 2012). Furthermore prevention of chronic HEV 
has been studied in a cohort of patients that are co-infected with HEV and the following 
haematological malignancies; acute leukaemia, non-Hodgkin lymphoma, multiple myelomas 
and others (Tavitian et al., 2015). Hence, patients with suppressed immune systems are 
likely to develop chronic HEV infection, which may lead to cirrhosis. Only HEV3 has been 
reported to induce chronic HEV infection (Kamar et al., 2012). 
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Figure 1.4 Course of HEV infection and serology responses (Kamar et al., 2012 with 
permission from Elsevier) 
 
1.2 Problem statement 
The prevalence of HEV infection worldwide may have previously been under-reported. Data 
investigating the prevalence of HEV in blood donors is particularly sparse. Blood donors are 
carefully selected clinically healthy individuals and usually have asymptomatic infections 
which allow for the blood-borne transmission of HEV to immunosuppressed blood 
transfusion recipients. The latter is a concern because unlike blood donors who are able to 
clear the virus infection, immunosuppressed recipients of HEV contaminated blood could 
develop chronic HEV infection caused by genotype 3. Previous work from our laboratory 
(Lopes et al., unpublished data) has shown a seroprevalence of 25.3% in blood donors from 
the Western Cape, South Africa. Based on this data we hypothesize that, blood donors may 
be infected with HEV in the past or currently and may thus potentially infect recipients of 
blood and blood products. 
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1.2.1 Hypothesis 
Blood donors with active HEV infection donate infected blood to recipients 
 Null hypothesis: 
- There is no evidence of active HEV infection amongst blood donors  
 
 Alternative hypothesis: 
- There is evidence of active HEV infection amongst blood donors  
 
1.2.2 Aims and objectives 
To determine 
 the prevalence of HEV infection in blood donors from the Western Cape 
 the risk factors associated with past HEV infection  
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CHAPTER TWO: LITERATURE REVIEW 
2.1 Epidemiology of HEV 
2.1.1 HEV worldwide 
HEV is the most common cause of acute viral hepatitis in many developing nations (Kumar 
et al., 2013; Isaäcson et al., 2000). Reports have shown that HEV causes large outbreaks of 
hepatitis in low to middle-income countries. The first reported outbreak was in India during 
1955 to 1956 and it resulted in 29,300 cases of hepatitis E (Viswanathan, 1957). However 
China had the largest outbreak of hepatitis E with 119,000 cases due to waterborne 
transmission (Zhang et al., 1991; Bi et al., 1993). During the mid-1990s, genotyping of HEV 
strains, led to the discovery that HEV1 was the primary cause of hepatitis E outbreaks in 
developing countries. HEV2 cases are the least reported and have been the cause of 
outbreaks in West Africa and Mexico (Teshale et al., 2010a). In developing countries people 
are frequently exposed to contaminated water and poor sanitary conditions, which causes 
waterborne outbreaks that are associated with HEV1 and HEV2.  
Until relatively recently hepatitis E was thought to be an imported disease in the developed 
world. However recent data has shown in Europe HEV infection may be occurring more 
frequently than previously thought. HEV3 and HEV4 have been reported in developed (Slot 
et al., 2013) and developing countries (Ren et al., 2013). These genotypes are associated 
with sporadic cases of HEV. Infection is thought to occur mainly via animal-to-human 
transmission by eating undercooked meat and less frequently via human-to-human 
transmission by blood transfusion (Purdy et al., 2011). In the Netherlands, a study was done 
which showed that 64% of hepatitis patients were infected with HEV locally (Koot et al., 
2015). The latter suggested that travel history to HEV endemic regions is not the only means 
of infection in developed countries. The estimated seroprevalence of HEV in developed 
countries has been reported to vary (Kamar et al., 2012) from less than 5% in the French 
blood donors (Boutrouille et al., 2007) up to 21% in civilians from the US (Kuniholm et al., 
2009). In support of this, Table 2.2 indicates that the difference is most likely due to different 
ELISA assays being used in studies. The epidemiology of HEV is very diverse and may be 
influenced by a number of factors that still need to be studied. 
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Figure 2.1 Global epidemiology of HEV infection and genotype distribution (Kamar et 
al., 2012 with permission from Elsevier) 
2.1.2 HEV in Africa 
Various outbreaks of hepatitis E have been documented in Africa. One of the earliest 
documented outbreaks occurred in Namibia in 1983. Individuals residing in settlements with 
limited water supply and unsanitary living conditions were greatly affected by the outbreak. 
After the investigation, it was reported to be non-A, non-B (NANB) hepatitis waterborne 
outbreak. Thereafter samples were obtained from jaundiced patients and healthy residents 
that were living in an affected settlement; to later determine the cause of the hepatitis 
epidemic. Subsequently, in 1998, the archived samples were tested for HEV markers. The 
tests showed that HEV RNA was detected in 56% of the faecal samples that were obtained 
from the jaundiced patients. Furthermore, 42% of the serum samples from the healthy 
individuals had anti-HEV IgM and 25% had total immunoglobulin that was tested using an 
ELISA (Genelabs Technologies, Inc., Redwood City, CA). The serology evidence of HEV 
infection in the healthy individuals was used to confirm that HEV was the causative agent of 
the hepatitis outbreak in 1983 (Isaäcson et al., 2000). In addition to this, phylogenetic 
analysis showed that the HEV strain isolated from the Namibia 1983 outbreak was HEV1 
(He et al., 2000). However a few years later in 1995, another outbreak occurred in the same 
region of Namibia and the four HEV strains from this outbreak belonged to HEV2 (Maila et 
al., 2004). 
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Madagascar  
A study was done to determine the prevalence of HEV antibodies in slaughterhouse workers 
and pigs in Madagascar. The results of the study revealed that anti-HEV IgG (MP 
Diagnostics, Illkirch, France) is highly prevalent in 71.2% of the swine in Madagascar. In 
addition to this, 1.2% of the pigs had detectable HEV RNA and were further analysed using 
phylogenetic analysis. The latter revealed that the viruses were HEV3 strains. It was 
suggested that the transmission of HEV from pigs to humans may have occurred in 
Madagascar. Serum samples of the slaughterhouse workers were tested with an ELISA 
assay (EIAgen HEV Ab, Adaltis, Milan, Italy) and 14% had evidence of past HEV infection. 
However the authors recommend that other non-zoonotic routes of HEV infection in humans 
should also be investigated (Temmam et al., 2013). 
Burkina Faso 
The burden of acute hepatitis caused by HEV and hepatitis A virus (HAV) was investigated 
in central Burkina Faso. The study population consisted of blood donors and pregnant 
women; that were used as a representative of the general population. Serum samples were 
obtained to test for antibodies to HAV and HEV. The anti-HAV IgG seroprevalence was 
found to be 14.3% in blood donors and 23% in pregnant women using an 
immunochromatographic assay (SD Bioline IgG, Standard Diagnostics, Inc., Korea). While 
the anti-HEV IgG seroprevalence in the blood donors was reported to be 19.1% and 11.6% 
in pregnant women, using the Dia.Pro ELISA kit (Dia.Pro Diagnostic Bioprobes S.r.l., Italy). 
Furthermore, the seroprevalence of HEV in Burkina Faso was found to be similar to that of 
other African countries such as; Tunisia (22%), Burundi (14%) and South Africa (15.3%) 
(Traoré et al., 2012) (Table 2.1). 
HEV and HAV share the faecal-oral route of transmission, which was also assessed during 
the above-mentioned study. However the findings showed that the prevalence of these two 
enteric viruses differed in immunocompetent i.e. blood donors and immunocompromised 
groups i.e. pregnant women (Traoré et al., 2012). A possible explanation was given for the 
higher HAV prevalence in pregnant women; it could have been caused by them having 
closer contact with children. The latter is as a result of children being susceptible to hepatitis 
A and could act as carriers of HAV to infect immunocompromised pregnant women (Smith et 
al., 1997). 
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Nigeria 
Researchers in Nigeria took a different approach to identifying which risk factors are 
associated with HEV infection. HEV and HAV are known to be similar because of their 
enteric transmission and their potential to serve as food pathogens (Collier et al., 2014). It 
was found that external factors may serve as a means of foodborne zoonotic transmission of 
HEV3. For example, when crops are grown with manure made from faecal matter of HEV-
infected animals or if the irrigation supply used to water the fruits and vegetables are from 
rivers contaminated with sewage, it may potentially contaminate the crops (Junaid et al., 
2014). Consequently, if fruits and vegetables are not washed before consumption it may 
increase the risk of getting infected with HEV. Junaid et al. reported that the latter was a 
statistically significant behavioural risk factor associated with past HEV infection (p-value, 
<0.001). The study has provided valuable insight into the epidemiology of HEV in West 
Africa and assessed risk groups to assist with public health prevention strategies in Nigeria. 
2.1.3 HEV in South Africa 
In the mid-1990s, an overall seroprevalence rate of 10.7% for anti-HEV was observed 
amongst 767 black South Africans living in urban and rural areas. An enzyme-linked 
immunosorbent assay (Abbott HEV EIA; Abbott Laboratories) was used to detect HEV 
antibodies to antigenic regions coded from ORF2 and ORF3 (Tucker et al., 1996). However, 
the assay was less sensitive than the current assays and may have underestimated the 
seroprevalence of HEV infection in South Africa.  
Two other reports of HEV infection in South Africa have previously been published: one 
report of a hospital outbreak caused by nosocomial transmission to medical staff who 
attended to a pregnant woman who had acquired hepatitis E while traveling aboard. The 
samples from this outbreak were tested for HEV antibodies using a western blot test 
performed at the CDC Hepatitis Laboratory in the US (Robson et al., 1992). The other report 
in medical students and canoeists used an EIA with synthetic peptides to detect HEV 
antibodies (Grabow et al., 1994). The results of these reports are shown in Table 2.1. These 
studies did not test for HEV RNA which indicates evidence of active infection, therefore, no 
genotyping was done. Since then advances have been made in molecular testing and 
current data have reported on the genotype of HEV strains found in South Africa. HEV3 has 
been found in an HIV-infected patient (Andersson et al., 2012) and more recently in a patient 
that received a renal transplant (Andersson et al., 2015). In addition, to this a case of HEV1 
was isolated from a patient after visiting an HEV-endemic country (Andersson et al., 2015). 
Further investigations are required to better understand the epidemiology of HEV. 
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Table 2.1 HEV prevalence in sub-Saharan Africa 
Reference Country Prevalence Cohort HEV 
genotype 
Jacobs et al., 
2014 
 
Zambia 
42% 
(N=106) 
Co-infected HEV-
HIV Adults  
Not reported 
(NR) 
 
 
Teshale et al., 
2010a 
 
 
 
Uganda 
 
 
64% 
(N=475) 
Residents from 2 
sub counties in 
Uganda affected 
by the epidemic 
 
 
 
1 
 
Maila et al., 
2004 
 
Namibia 
 
(N=4) 
 
Outbreak 1995 
 
2 
Isaäcson et al., 
2000; He et al., 
2000 
 
 
Namibia 
 
25% 
(N=24) 
Healthy residents 
from a severely 
affected 
settlement 
 
 
1 
 
Tucker et al., 
1996 
 
 
South Africa 
10.7% 
(N=767) 
407 urban adults 
(5.8%)  
360 rural adults 
(19.1%)  
 
Blacks from rural 
& urban areas 
 
 
NR 
 
 
Van Rensburg 
et al., 1995 
 
 
 
Swaziland 
4% (Ndzevane) 
(N=NR) 
2% (Malindza) 
(N=NR) 
 
398 Mozambican 
refugees from 
Two camps 
 
 
 
NR 
Grabow et al., 
1994 
 
South Africa 
2.05% 
(N=782) 
Canoeists & 
Medical students 
 
NR 
Byskov et al., 
1989 
 
Botswana 
1-2% 
(N=273) 
Hepatitis & 
jaundiced adults 
 
NR 
 
2.2 HEV in blood donors 
Blood safety is an important issue in the world and ensuring blood products are free from 
any infection is a priority. Over the past few years, there has been much attention paid to the 
risk of HEV transmission from blood products. 
2.2.1 Prevalence of HEV in blood donors  
The International Society of Blood Transfusion very recently published an International forum 
issue on Hepatitis E to address several questions on screening blood donations for HEV 
infection. They received a response from 18 institutions within 16 different countries; 12 
developed and 4 developing (Petrik et al., 2015). This forum has summarised both 
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seroprevalence and RNA incidence data on HEV infection and reflects that the majority of 
the data is from anti-HEV IgG findings i.e. past HEV infection with very little or no data on 
anti-HEV IgM and HEV RNA indicating a recent or active HEV infection. The latter being 
crucial is determining the risk of HEV transmission via blood transfusion and also required 
for genotyping to determine the route of transmission. Subsequently by knowing the risk 
factors associated with acquiring HEV infection, it can help with prevention in the general 
population and effective screening strategies of blood donors and recipients.   
2.2.1.1 HEV prevalence in blood donors from developed countries 
England and Wales 
In several developed countries such as England, serological and molecular tests were 
performed in a study cohort of English and Welsh blood donors. The cohort consisted of 262 
donors from the National Health Service (NHS) Blood and Transplant and 333 samples from 
donors that were hepatitis B virus core antibody negative with past evidence of jaundice. 
Samples were tested for anti-HEV IgG and IgM; if the result was anti-HEV IgG positive. 
Additionally, an in-house TaqMan assay was used to test for HEV RNA. Overall the study 
showed that 10% of the blood donors were anti-HEV IgG positive which was linked to an 
increase in age with males and females. In addition to this, IgM reactive donors had no 
detectable HEV RNA which would have suggested recent active HEV infection (Beale et al., 
2011).  
France 
Blood donors (N=512) from Midi-Pyrénées in France, completed a risk factor questionnaire 
and were tested for HEV antibodies. In addition to this, pig liver sausages from the local 
market in Midi-Pyrénées were tested for HEV RNA. According to the results, the 
seroprevalence of 52.5% using the Wantai assay [95%CI, 48.2-56.8] for HEV IgG antibodies 
is the highest reported for a high-income developed country. The HEV risk factor data 
showed that old age, rural residence, having direct contact with a cat and hunting game (wild 
boar or deer) was significantly associated (p-values <0.05) with the foodborne zoonotic 
transmission. HEV RNA was detected in some of the pig liver sausages and the strains 
belonged to HEV3 (Mansuy et al., 2011).  
Another study reported on the seroprevalence of past HEV infection in blood donors from 
southern France and south-west France was found to be 39.1% with the Wantai assay 
[95%CI, 37.4-40.7] and 52.5% [95%CI, 48.2-56.8] respectively. Southern France has two 
regions; 1,897 of the blood donors from Midi-Pyrénées and 1,456 from Languedoc-
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Roussillon had to complete a questionnaire. The four factors were found to be associated 
with HEV infection namely; eating raw pork liver sausages (p<0.001), offal (p=0.003) and 
shellfish (p=0.02). Hence, their results show that there is more than one main risk factor 
associated with HEV infection and many possible sources of contamination in southern 
France. However, more importantly, the incidence of HEV in blood donors from these two 
regions indicate that their annual number of blood donations has at least 148 of 184,000 
donations that may be HEV RNA positive. Although not much is known about risks of 
transfusion-transmitted HEV infections in southern France (Mansuy et al., 2015). 
Greece 
In Athens, Greece 265 donors were tested for antibodies to HEV IgG using an ELISA kit 
(EIAgen, Adaltis Inc., Italy) and the seroprevalence was found to be 9.43%. All the HEV 
seropositive (25/265) blood donors were from urban areas with no recent history of traveling 
outside of Greece. No HEV molecular testing was done on the IgG positive samples to 
determine which strain of HEV is circulating in Greece. However judging by the literature it is 
most likely to be genotype 3 because it is frequently associated with infection in individuals 
from developed countries without any travel-history to developing countries. Further studies 
should test the animals in Greece for HEV RNA reveal whether the zoonotic transmission is 
occurring via direct contact with HEV-infected animals or consumption of undercooked 
infected meat (Pittaras et al., 2014).  
Denmark 
The seroprevalence of HEV in blood donors was monitored over time by comparing the data 
of three studies using an in-house ELISA developed at National Institutes of Health (NIH 
assay). The advantage of using the same assay to evaluate the prevalence at different time 
points in the same population has eliminated the problem of assay variation. To indicate the 
decline in anti-HEV IgG, three blood donors from the 2003 study were included in the 2013 
study; two donors may have experienced a waning of their antibodies since initially they 
were seropositive and after a decade, their antibody levels were below the assay sample 
cut-off (S/CO) value. However, one of the three donors from the 2003 study remained 
seropositive. Therefore, they concluded that even though there has been a major decline in 
the prevalence of HEV from 32.9% in 1983 to 10.7% in 2013, the prevalence in Denmark is 
still fairly high and blood donors should be screening for HEV infection (Holm et al., 2015). 
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Table 2.2 HEV prevalence in blood donors from high income (developed) countries 
Country Sample size HEV IgG 
seroprevalence 
HEV RNA 
prevalence 
Reference 
United States 
(US) 
18,829 blood 
donations 
329 of 4,499 (7.3%) 
MP Biomedicals 
assay 
[95%CI,6.6-8.1] 
2 of 18,829 
(0.01 %)  
Procleix assay 
Stramer et 
al., 2015 
Southeast 
England 
225,000 blood 
donations 
= 9,382 Minipools 
23 of 79 (29%)  
Wantai assay 
79 of 225,000 
(0.04%)  
Hewitt et al., 
2014 
Spain 9,998 blood 
donations 
(19.96%) Wantai 
assay and (10.72%) 
Mikrogen assay 
3 of 9,998 
(0.03%) 
Procleix assay 
Sauleda et 
al., 2015 
France 53,234 blood 
donations 
= 558 Minipools  
 (23.6%)  
Wantai assay 
24 of 53,234 
(0.045%)  
Gallian et al., 
2014 
Australia 
 
 
3,237 blood 
donations 
194 of 3,237 
(5.99%)  
Wantai assay 
[95%CI,5.18–6.81] 
No RNA 
positives  
Procleix assay 
Shrestha et 
al., 2014 
Scotland 43,560 blood 
donations = 1,815 
Minipools 
73 of 1,559 
(4.7%) Wantai assay 
[95%CI,3.6-5.8] 
3 of 1,815 
minipools 
(0.2%)  
Cleland et 
al., 2013 
Netherlands 45,415 blood 
donations  
1,401 of 5,239 
(27%) Wantai assay 
17 of 45,415 
(0.04%) 
Slot et al., 
2013 
US 1,939 blood 
donations 
364 of 1,939 
(18.8%)  
Wantai assay 
[95%CI,17.0-20.5] 
No RNA 
positives 
Xu et al., 
2013 
  
Saudi Arabia 900 blood 
donations 
168 of 900 (18.7%) 
Bioelisa assay 
Not done (ND) Johargy et 
al., 2013 
England 42,000 blood 
donations = 880 
Minipools 
~13% (Ijaz et 
al.,2009) 
6 of 880 
minipools 
(0.7%)  
Ijaz et al., 
2012 
Germany 16,125 blood 
donations 
*Minipools of 48 
Donors with ↑ ALT 
(5.9%) RecomLine 
assay 
13 of 16 125 
(0.08%)  
Vollmer et 
al., 2012 
Switzerland 550 blood 
donations 
27 of 550 (4.9%)  
MP Diagnostics 
assay 
ND Kaufmann et 
al., 2011 
Japan 6,700 blood 
donations 
479 of 6,700  
(7.1%)  
9 of 6,700 
(0.1%)  
Gotanda et 
al., 2007 
Japan 5,343 blood 
donations 
200 of 5,343 (3.7%) 
in-house assay 
3 of 5,343 
(0.06%)  
Fukuda et 
al., 2004 
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2.2.1.2 HEV prevalence in blood donors from developing countries 
There is little data describing the prevalence of HEV in blood donors from developing 
countries (Table 2.3). 
China  
In China, a study specifically looked at the risk of being infected with HEV through blood 
transfusion. The results showed that 2 of the 10,741 (0.02%) donors with normal ALT levels 
were possibly exposed to HEV and at risk of having undetectable viremia. Furthermore, in 
support of this 2 of the 4 HEV RNA positive donors had normal ALT levels and were most 
likely tested during the window period of HEV infection. Blood donors with elevated ALT 
levels had a significantly higher seroprevalence than normal donors, for both anti-HEV IgM 
and IgG, (Wantai Biopharmaceutical, Beijing,China) with a p-value of <0.01 for both these 
HEV markers. However there was no significant difference seen for the HEV antigen 
although it also had a higher prevalence in blood donors with elevated ALT levels, the p-
value was equivalent to 0.10 > 0.05. Overall the results showed that two of the donors with 
elevated ALT levels had detectable HEV RNA, suggesting that it is not a very reliable marker 
for active HEV infection (Ren et al., 2013).   
India 
Four hundred and sixty male blood donors in India were tested for IgM antibodies to HEV 
(Diagnostic Bioprobes Srl, Milano, Italy). The findings indicated that they had a 4.78% anti-
HEV IgM seroprevalence rate (Gajjar et al., 2014). However the 22 IgM HEV positive donors 
were not screened for HEV RNA but previously in Pune, India the HEV RNA prevalence was 
found to be 1.5% (3 of 200) (Arankalle et al., 2000). Gajjar et al. compared their HEV 
seroprevalence rate to several other HEV studies done in blood donors and had a similar 
prevalence as Switzerland of 4.9% (Kaufmann et al., 2011). The difference HEV 
seroprevalence of developing and developed countries was discussed by stating that it may 
be due to the different HEV routes of transmission. Waterborne transmission being most 
common in developing countries as opposed to foodborne zoonotic transmission however 
study population also plays a role.  
Brazil 
A seroprevalence study was done in a metropolitan area with a cultural preference for 
frequently eating pork meat products. Recent and past HEV infection was investigated in 
300 blood donors tested for anti-HEV IgG and IgM. Thirty of the donors were positive for 
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anti-HEV IgG and these donors were subsequently tested for IgM antibodies (Wantai 
Biopharmaceutical, Beijing, China). One of the 30 seropositive IgG donors tested positive for 
IgM, suggesting that past HEV infection was more prevalent than recent infection. 
Furthermore, the presence of both IgG and IgM in the latter donor could indicate that 
seroconversion was taking place or it might have been a re-infection. There were no HEV 
RNA positive donors identified with active HEV infection (Passos-Castilho et al., 2015). 
2.2.1.3 HEV prevalence in blood donors from Africa 
Egypt 
In the general population, it was found that Egyptians who live in rural villages have acquired 
natural immunity to HEV which is suggested by the prevalence of anti-HEV antibodies in 
67.7% [95%CI, 66.7-68.6] using the Abbott HEV ELISA kit (Fix et al., 2000). However 
contrary to the high prevalence in the general population the findings from Ibrahim et al. 
suggested that there is a low seroprevalence of HEV among blood donors in Egypt. 
Nevertheless, the latter study has shown that there is evidence of recent and active HEV 
infection in blood donors. Anti-HEV IgM antibodies were detected in 3 of the 760 blood 
donors using the MP diagnostic assay and 2 of these 3 blood donors had detectable HEV 
RNA, (2/760) 0.26%. Hence, the general population, in particular, healthy individuals such as 
blood donors have asymptomatic HEV infection. In addition to this it is also evident that the 
prevalence of HEV will tend to vary because if individuals do not present with symptoms, or 
if they are not blood donors (Ibrahim et al., 2011) or recruited to participate in a community 
serosurvey (Fix et al., 2000) then the true seroprevalence will most likely remain 
underestimated.  
Another study was done two years, later on, a smaller study population of blood donors 
(N=488). The total seroprevalence of the study was reported to be 20.9% (102/488) for both 
anti-HEV IgM and IgG. However, all the seropositive samples tested for HEV RNA had an 
undetectable viral load. The blood donors in Ismailia, Egypt had no active HEV infection, but 
they had a higher HEV seroprevalence (Tadesse et al., 2013) than the blood donors from 
Ibrahim et al. with 0.39% (3/760). Thus, the difference in HEV seroprevalence for blood 
donors from Egypt appears to vary and has reached as high as 45.2% in blood donors 
(Abdel Hady et al., 1998). Concluding that Egyptian blood donors have one the highest HEV 
seroprevalence rates worldwide and specifically in Africa. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
20 
 
Ghana 
The seroprevalence in Ghana was observed to be 4.6% for anti-HEV IgG by using three 
ELISA assays [(Mikrogen, Neuried, Germany); (Fortress Diagnostics, Antrim, UK); (MP 
Biomedicals, Illkirch, France)]. Furthermore, molecular tests were done on all the reactive 
samples in individual reactions and in the non-reactive samples in pools of 10 donations. 
However none of the samples tested in the study were found to be HEV RNA positive 
(Meldal et al., 2013). Therefore, no genotyping could be done to investigate the possible 
routes of HEV transmission in Ghana. Nonetheless, it is suspected that the poor sanitary 
conditions together with the regular occurrence of floods in Ghana may induce the spread of 
HEV1 and HEV2. However, there is insufficient information to evaluate the number of 
outbreaks that may have been caused by the waterborne transmission (Meldal et al., 2013). 
Further studies are needed to confirm the current data that exists on the prevalence and 
epidemiology of HEV in blood donors from developing countries, such as Ghana. 
South Africa 
In 2013 we investigated a small sample of blood donors in the Western Cape, comprising 
100 samples that were randomly selected from each of the three different race groups of 
blood donors, of different sex and different age groups. The blood donors were tested for 
anti-HEV IgG and IgM using an ELISA (Fortress Diagnostics, UK) and subsequently tested 
for HEV RNA in plasma mini pools of 10. Of the 300 samples 76 were positive for HEV IgG, 
with a total seroprevalence of 25.3% [95%CI, 20.1-29.9]. There was a trend toward a higher 
seroprevalence in coloured men with a statistical significance in those 26-45 years (p<0.05) 
and those older than 46 years (p<0.001). None of the samples were positive for anti-HEV 
IgM and none of the mini pools had detectable HEV RNA (Lopes et al., unpublished data). 
This allowed us to describe for the first time, demographic risk factors which may be 
associated with HEV infection. However, the sample size was not large enough to assess 
the risk of active HEV infection, but sufficient to indicate that there may be a problem which 
deserves further attention. 
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Table 2.3 HEV prevalence in blood donors from low to middle income (developing) 
countries 
Country Sample size HEV IgG 
Seroprevalence 
HEV RNA 
prevalence 
Reference 
Egypt 488 blood 
donations 
102 of 488 
(20.9%)  
Dia.Pro assay 
No RNA 
positives 
Tadesse et al., 
2013 
Ghana 239 blood 
donations  
 
11 of 239 (4.6%) 
Wantai and 
recomWell assays 
No RNA 
positives 
*Plasma pools 
of 10 
Meldal et al., 
2013 
Iran 530 blood 
donations 
76 of 530 (14.3%) 
Dia.Pro assay 
ND Ehteram et al., 
2013 
Burkina Faso 178 blood 
donations 
(19.1%) Dia.Pro 
assay (14.6%) 
Wantai assay 
[95%CI,13.3-24.9] 
ND Traoré et al., 
2012 
Tunisia 687 blood 
donations 
(5.4%) MP 
Diagnostics assay 
ND Houcine et al., 
2012 
China 44,816 blood 
donations 
14,608 of 44,816 
(32.6%)  
Wantai assay  
30 of 44,816 
(0.07%)  
Gou et al., 
2010 
Brazil 996 blood 
donations 
23 of 996 (2.3%) 
Abbott assay 
[95%CI,1.5-3.5] 
ND Bortoliero et al., 
2006 
 
2.3 Risks and consequences of HEV in blood donors 
2.3.1 HEV infection associated with blood transfusion 
Blood donations are crucial to saving the lives of patients in need of blood or blood-derived 
products. Hence, blood donation services have a selection criterion to ensure the safety of 
blood and blood products. However, the possibility of a recipient receiving blood or blood 
products that are contaminated with HEV is a growing concern. 
In the United States (US) researchers have assessed the risk of HEV transfusion-transmitted 
infection (TTI) by testing blood donor samples (N=1,939) for active HEV infection and they 
monitored the recipients (N=362) of these blood donations. The recipients were tested for 
HEV markers (IgM and IgG antibodies and viral RNA) before and after having the blood 
transfusion. The researchers concluded that none of the blood donors had detectable HEV 
RNA and consequently the recipients had no cases of TTIs (Xu et al., 2013). This study is 
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one of the few studies that have included the recipients of blood donations to get a better 
understanding of the blood-borne transmission of HEV infection.   
In addition to the above-mentioned study, a larger study was done in the UK to investigate 
the prevalence of HEV in donors and to determine the incidence of HEV TTIs in the blood 
recipients. Two hundred and twenty-five thousand individual blood donations from donors in 
southeast England were retrospectively screened during the study to detect blood donations 
containing HEV RNA. Follow-up was also done by the National Health Service Blood and 
Transplant (NHSBT) to identify, inform and monitor recipients of the blood components that 
were received from HEV viraemic donors. Of the 225,000 donations tested for HEV RNA, 79 
had detectable HEV and 129 blood components were made. Furthermore, these HEV 
contaminated blood components had already been transfused to 60 recipients. 
Subsequently, follow-up was done and they were able to recruit 43 of which 18 recipients 
(42%) that had evidence of HEV transmission. Furthermore to confirm that it was 
transfusion-associated HEV infection, the sequences obtained from the viraemic donors 
(N=54) and recipients (N=12) were compared using a phylogenetic tree. As a result, all the 
sequences were found to be HEV genotype 3 and the donor and recipient sequences were 
identical (Hewitt et al., 2014). 
In Canada efforts have been made to evaluate the risk of HEV transmission in thrombotic 
thrombocytopenic purpura (TTP) patients that received large volumes of plasma, up to 40 
litres for treatment. The results indicated that 4 of 17 patients who received solvent-
detergent-treated plasma (SDP) had seroconverted to IgG at six months post-treatment. 
Thus suggesting that plasma-derived blood products given as treatment may potentially 
permit the transmission of HEV. Due to the absence of the SDP residual samples, the 
researchers were unable to do sequencing analysis to check for homology between the SDP 
units used and the patient samples. The two patients with IgG seropositivity and detectable 
HEV RNA in the 1-month post-treatment samples received the same SDP unit hence the 
researchers concluded that there is indirect evidence of HEV TTI via plasma (Andonov et al., 
2014). However further studies are required to confirm this by firstly having access to both 
the donor and patient samples to provide a direct link between the infected donor blood 
components causing infection in a patient if they have detectable viral RNA. Secondly to 
distinguish between actively and passively acquired antibody if a patient test antibody 
positive. 
It is therefore requested that the blood donors report back to the blood donation clinic when 
they experience any signs and symptoms of viral hepatitis infection (Boxall et al., 2006). In 
the unlikely event that a blood donor is infected, there is a critical time period available in 
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which to prevent the transfusion of their infected blood or blood products. A recipient could 
be spared the fate of being infected and having their health deteriorate rapidly. Studies have 
reported that it is advantageous to have the records of both blood donors and their 
recipients. The latter is required to determine whether the blood donor and their recipient 
have sequence identity and to confirm whether HEV blood-borne transmission occurred 
(Khuroo et al., 2004). 
2.4 Prevention of HEV TTIs 
2.4.1 HEV screening of blood donations 
HEV can be transmitted through transfusion of blood and blood products. Studies have 
reported that HEV3 has been detected in blood donors from developed countries (Cleland et 
al., 2013; Vollmer et al., 2012; Slot et al., 2013) as well as HEV4 in a transfusion-transmitted 
HEV case (Matsubayashi et al., 2008). Whilst highly sensitive HEV screening methods are 
available (Vollmer et al., 2012), it would be costly to individually screen the blood donor 
supply for HEV infection. Using a pooling strategy would be less expensive and could be 
suitable to screen large populations with low seroprevalence (Lui et al., 1997).  
2.4.1.1    Current screening in South Africa 
SANBS (Vermeulen et al., 2009) and WPBTS (Cable et al., 2013) routinely screen for HIV-1, 
HIV-2, HBV, HCV and also syphilis. Prior to each blood donation, the donor has to complete 
a confidential questionnaire with lifestyle and health related questions. Thereafter the donor 
may donate blood that gets tested for serology markers (anti-HIV, HBsAg and anti-HCV) on 
the Prism analyser (Abbott, USA) using the Ultrio assay (Cable et al., 2013) and for 
molecular markers (HIV RNA, HBV DNA and HCV RNA) on the Panther system (Hologic 
Inc., USA). The South African Blood transfusions do not routinely screen blood donations for 
HEV. 
2.4.2 HEV surveillance 
One of the most valuable prevention strategies for HEV TTI is haemovigilance. This is a 
surveillance system that aims to ensure the quality and safety of all blood transfusion 
products. Haemovigilance systems should, therefore, exist in all regions where blood 
transfusion procedures take place. However due to significant differences in the economy, 
infrastructure and governance of different countries, it is quite challenging to have 
standardised haemovigilance systems implemented worldwide. Nevertheless existing 
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haemovigilance systems are functioning well in certain countries irrespective of the variability 
in these systems which need to be addressed.  
The two European programmes namely; the Agence Française de Sécurité Sanitaire des 
Produits de Santé (AFSSAPS) and Establissement Français du Sang (EFS) national system 
in France and the Serious Hazards of Transfusion (SHOT) national system in the UK, serve 
as haemovigilance models for other countries. These systems operate in a centralised 
national scheme which is ideal and report adverse transfusion reactions on either a 
mandatory (France) or voluntary basis (UK). This is reflected in the number of HEV TTIs that 
have been reported, from France (N=5) and UK (N= 19), summarised in Table 2.4. 
Table 2.4 Haemovigilance systems in countries with HEV TTIs 
Country Haemovigilance 
System / 
Surveillance 
Notification 
of adverse 
blood 
transfusion 
incidents 
Number of HEV TTIs 
reported in country 
References 
France  Yes Mandatory 5  
Germany Yes Mandatory  - Juhl et al., 2014 
UK Yes Voluntary 1 Boxall et al., 
2006 
UK Yes - 18 Hewitt et al., 
2014 
Japan Yes    Voluntary 5  
India Yes Mandatory 1 Arankalle et al., 
2000 
Saudi Arabia Yes - 1 Khuroo et al., 
2004 
China Yes - 1 Ren et al., 2013 
 
2.4.3 HEV vaccine 
The development of an HEV vaccine is required to provide immunity to individuals that are at 
a higher risk i.e. particularly blood transfusion recipients that are immunosuppressed 
patients, the elderly, pregnant women and children (Kamar et al., 2012; Dreier et al., 2014). 
HEV vaccine trials done in Nepal and China have identified candidate vaccines which prove 
to be effective (Kamar et al., 2012). There are two HEV vaccines which have been 
manufactured; by GlaxoSmith Kline and Xiamen Innovax Biotech.  
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The Hecolin (HEV239) vaccine developed by Xiamen Innovax Biotech was registered after 
completing an initial 19-month efficacy study (Zhu et al., 2010) and has been administered in 
China since 2012. The vaccine was given at time points 0, 1 and 6 months and developed 
using HEV1. An extended efficacy study was done to observe the long-term effect and the 
following factors were assessed; the efficacy, safety and immunogenicity of the Hecolin 
vaccine. The antibody response against HEV was protective and lasted up to four and a half 
years (Zhang et al., 2015). However, the safety in high-risk groups has not been reported.          
There are nevertheless certain things to take into consideration when developing an 
effective HEV vaccine and making it available worldwide. Firstly since HEV has different 
routes of transmission which are associated with HEV1 to HEV4 and this should be 
considered when determining the efficacy of the vaccine. Secondly, the time points when the 
vaccine should be given to the respective groups that are susceptible to HEV infection need 
to be established. Lastly there should be adequate funding to implement the HEV 
vaccination programme, especially in endemic developing regions and could it be part of the 
already existing viral hepatitis vaccines i.e. hepatitis A and hepatitis B to be given in 
combination as Twinrix which is licensed in the United States (Centre for Disease Control 
and Prevention, CDC). 
2.5 Treatment of HEV infection 
HEV infection is generally acute and self-limiting, however, immunosuppressed patients that 
are chronically infected need therapy to destroy the HEV-infected cells. The main concern of 
chronic viral hepatitis infection is the possibility of it leading to cirrhosis and eventually 
evolving to hepatocellular carcinoma (HCC). 
There are two main types of treatment recommended for patients with chronic HEV infection. 
Ribavirin and pegylated interferon have been reported to be effective in solid-organ 
transplant recipients receiving therapy for 3 months (Kamar et al., 2014; Kamar et al., 
2010a). According to Kamar et al. after consecutive studies on the treatment of chronic HEV 
infection in transplant recipients, ribavirin is appropriate to use in all solid-organ transplant 
recipients. However pegylated interferon- alpha has adverse effects on kidney transplant 
recipients and may induce acute kidney failure (Kamar et al., 2010b). 
Treatment of chronic HEV infection aims to ultimately eradicate HEV replicating cells and to 
avoid retransplantation of solid-organs particularly the liver. However it has been reported 
that chronic HEV infection could reoccur in patients undergoing retransplantation of the liver 
(Haagsma et al., 2009). In some instances while patients are on treatment with either 
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ribavirin or pegylated interferon relapse occurs during or after the 3-month course of therapy 
(Kamar et al., 2010a; Kamar et al.,2010b; Kamar et al., 2014). Haagsma et al. had two case 
reports of chronic HEV infection in liver transplant recipients receiving pegylated interferon 
alpha-2b and during the study period, none of the patients had a recurrence of HEV 
infection. However it is important to bear in mind that patients respond differently to 
treatment and depending on their medical condition patients are given different optimal 
dosages of the prescribed therapy to ensure safety and efficacy (Kamar et al., 2014). 
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CHAPTER THREE: MATERIALS AND METHODS 
 
I. Materials 
3.1 Ethical aspects 
Ethics approval was obtained for this project from the Health Research Ethics Committee 
(HREC) of Stellenbosch University on 23 June 2014 (reference number: S14/04/09) and 
renewed the following year.  
3.2 Study design 
This was a prospective study to determine the prevalence of past and active hepatitis E virus 
(HEV) infection in blood donors in the Western Cape and to assess risk factors associated 
with HEV status. 
Two sub-studies were conducted: study group 1 consisted of 250 donors from 25 randomly 
selected blood donation clinics in Cape Town and its surrounding areas. Participants 
consented to completing a risk factor questionnaire (Addendum 1) and to being tested 
serologically for HEV IgG antibodies and molecularly for HEV RNA. Test results were 
correlated with demographic and behavioural factors as per questionnaire responses to 
identify risk factors associated with HEV infection (Addendum 2). All samples were tested 
individually for the presence of anti-HEV IgG antibodies as a marker of past infection. In 
addition 25 plasma minipools of 10 donations per pool were tested by an in-house real-time 
reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR) for the presence of 
HEV RNA as a marker of active infection. Study group 2 consisted of 10,000 donors from 
blood donation clinics across the Western Cape who had their individual donations (ID) 
screened for HEV RNA using a qualitative transcription-mediated amplification (TMA) assay 
(Procleix HEV assay, Grifols Diagnostic Solutions Inc., Spain) on an automated machine 
(Panther system, Hologic Inc., USA) at the routine virology laboratory of the Western 
Province Blood Transfusion Service (WPBTS).  
3.3 Sample collection 
3.3.1    Study group 1: blood donors that donated blood and completed the questionnaire 
These 250 donors were recruited and consented over a period of three months from 
September 2014 to December 2014. We randomly selected and attended blood donation 
clinics from the WPBTS clinic schedule in Cape Town and the surrounding areas. We 
received the corresponding blood samples from the 250 questionnaire donors after the 
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WPBTS virology laboratory had tested the blood for HIV, HBV, HCV and syphilis as per 
routine screening protocol. The blood samples that we received were the primary donor 
tubes which remained after the donors' blood had been tested by WPBTS. The 250 blood 
samples were tested at our division for anti-HEV IgG and then pooled to test for HEV RNA. 
3.3.2    Study group 2: blood donors that only donated blood  
We tested 10,000 blood samples from donors at WPBTS blood donation clinics across the 
Western Cape. These samples were collected from all blood donation clinics that were 
scheduled from October 2015 to November 2015. The criteria for inclusion in the study were 
as follows: any blood donor who donated a full pint of blood and underwent the WPBTS 
routine screening. Following the routine screening, the 10,000 samples were tested for HEV 
RNA on the Panther system (Hologic Inc., USA) at the virology laboratory of WPBTS. Only if 
a donor sample tested positive for HEV RNA, he or she was identified by WPBTS, 
counselled and given the option to complete our study HEV risk questionnaire. 
 
Figure 3.1 Selection and sampling of study participants 
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3.4 Study questionnaire 
The study questionnaire (Addendum 2) was designed to assess the risk factors associated 
with HEV exposure in volunteer donors from the WPBTS blood donations clinics surrounding 
Cape Town. It contained 59 variables within 6 categories namely: demographics, medical 
history, travel history, food consumption, water consumption and contact with surface water 
and animal contact. After the data was captured in an Excel spreadsheet it was combined 
with the serology results to identify risk factors associated with HEV infection.  
3.4.1 Questionnaire formatting 
The questions in our study questionnaire were sourced from validated HEV risk assessment 
questionnaires namely; the Dutch questionnaire (Verhoef et al., 2012), the Public Health 
England (PHE) national HEV questionnaire and the Hepatitis E National Case-Control Study 
Case questionnaire (S. Ijaz personal communication, 2014). We integrated the questions 
from these questionnaires and adapted the questionnaire to be more specific to determine 
the possible risk factors in our study participants. The questions were translated into 
Afrikaans and both the English and Afrikaans questionnaires trialled using the staff of our 
Division of Medical Virology. We received valuable feedback from this and subsequently 
made changes to clarify certain questions to avoid ambiguity. We also decided to administer 
the questionnaire in an electronic format to prevent human error and bias when the data was 
captured and to not have to decipher handwriting. The developer tab of Microsoft (MS) Word 
2010 was used to format the questionnaire as a fillable document by using check boxes, text 
boxes and etcetera. Another trial was done on blood donors at N1 City Mall WPBTS blood 
donation clinic in Cape Town on 22 September 2014 prior to starting the actual study. 
3.4.2 Selection process for blood donation clinics 
We used an online randomization tool (Random Integer Generator, 
http://www.random.org/integers/) to select 25 of the total 57 WPBTS blood donation clinics 
situated in Cape Town and the surrounding areas. Our aim was to get 10 donors from each 
of the 25 randomly selected clinics that are highlighted in grey in Table 3.1, to voluntarily 
complete the study questionnaire. The randomization was done to prevent selection bias by 
the principal investigator (PI) and also amongst the questionnaire participants. 
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Table 3.1 WPBTS blood donation clinics surrounding Cape Town 
1. Athlone 29.     Epping I  
2. Belhar 30.     Epping II 
3. Bonteheuwel 31.     Goodwood 
4. Grassy Park 32.     Kenridge 
5. Lotus River 33.     Kraaifontein 
6. Mitchells Plain 34.     Kuils River 
7. Ravensmead 35.     Maitland 
8. Steenberg 36.     Milnerton 
9. Vanguard Estate 37.     Monte Vista 
10. Cape Town 38.     Panorama 
11. CBD 39.     Parow 
12. Kensington 40.     Plattekloof 
13. Maitland 41.     Richwood 
14. N’dabeni 42.     Stellenberg 
15. Observatory 43.     Bergvliet 
16. Pinelands 44.     Claremont 
17. Salt River 45.     Constantia 
18. Sea Point 46.     Kenilworth 
19. Woodstock 47.     Lakeside 
20. Bellville 48.     Lansdowne 
21. Blackheath 49.     Newlands 
22. Bothasig 50.     Ottery 
23. Brackenfell 51.     Plumstead 
24. Bellville South 52.     Retreat 
25. Durbanville 53.     Tokai 
26. Edgemead 54.     Wetton 
27. Eerste River 55.     Wynberg 
28. Elsies River 56.     Rondebosch 
 
3.4.3 Conducting the survey at the blood donation clinics 
The PI travelled with the WPBTS staff to the 25 randomly selected blood donation clinics on 
the days that the clinics were scheduled. All blood donors have to complete the standard 
WPBTS consent form which states that they give permission for their blood to be tested and 
used for research purposes (Addendum 4). At each of the blood donation clinics, the 
following approach was used to voluntarily recruit donors for the questionnaire: The donor 
firstly had to meet all the WPBTS donation criteria and qualify as an eligible donor. 
Subsequently, any donor who was seated on a donation bed and had already been seen by 
a nursing sister was approached by the PI. The PI then briefly explained the purpose of the 
study and the questionnaire and asked the donors if they wanted to participate. All the blood 
donors that volunteered to participate completed a consent form (Addendum 1) in their 
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language of preference, i.e. English or Afrikaans. One of the WPBTS clinic staff members or 
a relative of the donor if present signed as a witness. Participants were given a copy of the 
signed form. Thereafter the PI conducted an interview to fill in the questionnaire on an 
individual basis. While the donors were being bled on the donation beds they were unable to 
complete the questionnaire themselves. Hence, the PI assisted the donors by reading the 
questions out loud to the donor. The majority of the questions were in a check box format 
and only required the donor to verbally motivate some of the “Yes” selected answers. All the 
interviews were conducted by the PI, who filled in the questionnaires on behalf of the blood 
donors on an electronic device using MS Word 2010. Each questionnaire was saved as an 
individual PDF file. 
II. Methods 
3.5 Study group 1: HEV serology testing 
The 250 blood donors in study group 1 filled in the HEV risk factor questionnaire and were 
tested for anti-HEV IgG and HEV RNA. No HEV serology was done for study group 2. 
3.5.1 HEV IgG ELISA 
The Wantai anti-HEV IgG enzyme-linked immunosorbent assay (ELISA) (Fortress 
Diagnostics, Antrim, UK) was used. This is a qualitative indirect ELISA method which uses 
labelled anti-human globulin conjugate to detect the IgG antibodies present in the plasma 
samples. The kit included a negative and positive control and in addition, to this we included 
an in-house HEV positive control patient sample from Tygerberg Hospital (Andersson et al., 
2015).  
The assay was conducted according to manufacturer's specifications (Fortress Diagnostics 
Antrim, UK). First, sample diluent provided with the kit is added to each well and incubated. 
The samples are diluted to stabilize the serum proteins that are present in the biological 
samples and reduce non-specific binding (http://www.immunochemistry.com/products/elisa-
solutions-1/elisa-sample-diluents.html).  
The anti-HEV specific antibodies in the plasma samples bind to the pre-coated HEV ORF2 
antigens in each well during the incubation. Thereafter the unbound serum proteins are 
washed off and horseradish peroxidase (HRP) conjugated rabbit anti-human IgG antibody is 
added and incubated. After the incubation, another wash step is done to remove all the 
unbound conjugate. Hence, only the conjugate that is bound to the antigen-antibody 
immunocomplexes formed in the previous incubation remains. Thereafter chromogen 
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solutions A and B are added to the wells. The urea peroxide from the chromogen solution A 
is reduced to water and Tetramethylbenzidine (TMB) from chromogen solution B is oxidised 
to a diimine that produces a blue colour in the presence of the antigen-antibody-anti-IgG 
(HRP) immunocomplex. Finally, sulphuric acid is added as a stop reagent, which changes 
the blue colour in the positive wells to yellow due to a drop in pH from alkaline to acidic 
(HEV-IgG [package insert]. Antrim, UK: Fortress Diagnostics; 2008). The absorbance values 
are measured with the ELx800 Absorbance Microplate Reader (BioTek Instruments Inc., 
USA). 
The Wantai (Wantai Biological Pharmacy Enterprise Co., Beijing, China) assay was used for 
our study because it is considered to be one the best anti-HEV IgG tests that are currently 
available (Yan et al., 2008; Bendall et al., 2010; Schnegg et al., 2013). The Wantai assay 
has good sensitivity as a result of the PE2 protein which is made up of 221 of the 660 amino 
acids from HEV ORF2. The recombinant proteins (42 amino acids of ORF2) in MP 
Diagnostics assay (MP Biomedicals, Singapore) and synthetic peptides (88 amino acids of 
ORF2) used in the Dia.Pro (Diagnostics Bioprobes S.r.l., Milan, Italy) have shorter sequence 
lengths than the PE2 protein used in the Wantai kits. As a result, of the longer amino acid 
length of PE2 more conformational epitopes can be recognized by HEV antibodies in test 
samples.  (Schnegg et al., 2013).  
A comparative study done by Bendall et al. (2010) found that the Wantai assay 100% 
sensitivity compared to the MP Diagnostics assay with 50%. Recently another comparison 
study was done using a newer improved version of the MP Diagnostics kit which reported 
that it had a similar sensitivity rate as the Wantai (Avellon et al., 2015). Furthermore Avellon 
et al. stated that overall the Wantai assay appears to have better sensitivity than MP 
Diagnostics when using sample panels from blood donors (Bendall et al., 2010; Schnegg et 
al., 2013) and better than the Adaltis assay (InGen, France) using samples from patients 
with acute HEV infection (Abravanel et al., 2013; Avellon et al., 2015). 
3.5.2 Anti-HEV IgG test procedure 
The test was conducted as per manufacturer's instructions. The samples were tested in 
batches using half plates (48 of the 96 wells) at a time. Prior to starting the procedure all the 
samples that were stored at -20°C and the kit reagents stored at 4°C were thawed at room 
temperature for 15 to 30 minutes. A 5% wash buffer was freshly prepared in a 500 ml flask 
for each set of 48 wells which included the 6 controls and 42 donor samples tested as a 96 
well half plate. The ELISA procedure is shown below in Figure 3.2. 
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Figure 3.2 Step by step procedure of the HEV IgG ELISA   
STEP 1
100 µl of sample diluent was added to each well. 
STEP 2
10 µl of sample was added into the individual wells, starting from 
well F1.
STEP 3
Then 10 µl of the negative control was added into wells (A1,B1 
and C1) and the positive control was added into wells (D1 and 
E1).
STEP 4
Thereafter the plate was sealed with the cover provided with the 
kit and incubated at 37°C for 30 minutes.
STEP 5
A wash step was done whereby the wells were soaked for 30 
seconds, which was repeated for 5 wash cycles. 
STEP 6
100 µl horseradish peroxidase (HRP) conjugated rabbit anti-
human IgG antibody was added and incubated at 37°C for 30 
minutes.
STEP 7
Another wash step was done for 5 cycles, soaking the wells for 
30 seconds during each wash cycle.
STEP 8
50 µl of chromogen solution A [urea peroxide] and 
B [tetramethyl benzidine (TMB)] was added to the wells and 
incubated at 37°C for 10 minutes.
STEP 9
50 µl of sulphuric acid was added to each well.
STEP 10
The absorbance values of each well was measured at 450 nm 
with a reference wavelength of 630 nm.
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3.5.3 Quality control and interpretation of results 
After the test was completed and the optical density (OD) values of the wells had been read, 
the cut-off value was calculated as follows: mean OD value of the three negative controls 
included in each run plus a constant of 0.16 which is used for every batch of kits as 
stipulated by the kit manufacturer. 
Individual OD values for each sample were then divided by the cut-off value. If the ratio was 
<0.9 the result was negative; if it was >1.1 positive; and ratios between 0.9 and 1.1 were 
regarded as borderline. For a test to be valid the OD value of the negative control has to be 
<0.100 and the positive control has to be ≥ 0.800. According to manufacturer's instructions 
samples with borderline results should be re-tested in duplicate. We re-tested them in 
singlicate, using a previously unused kit to ensure that all reagents were fresh and the risk of 
possible contamination minimal. 
 
Figure 3.3 HEV serology testing for study group 1 
 
3.6 Study group 1: HEV molecular  testing 
An in-house real-time RT-qPCR assay established at the Division of Medical Virology, 
Faculty of Medicine and Health Sciences (FMHS) of Stellenbosch University was used to 
screen for active HEV infections in study group 1. To save cost, and given the expected very 
low prevalence of HEV RNA positivity in this group, samples were pooled before RNA 
extraction and PCR testing. 
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3.6.1 Pooling procedure 
We used a pooling strategy to test 25 minipools of ten samples each, instead of 250 
individual samples. PCR pooling strategies are used to reduce the cost of screening for viral 
RNA detection (Lui et al., 1997). To generate the minipools, 100 µl of plasma from each of 
10 donor samples was added to a 2 ml tube, with each pool having a total volume of 1 ml. 
Pooled samples were mixed thoroughly using a vortex for 1 minute and thereafter stored at 
4°C until extraction of viral RNA the following day. Our pooling strategy of 10 samples per 
minipool (Ijaz et al., 2012) has previously been validated during a pilot study; the limit of 
detection (LOD) was 3,000 IU/ml as the lowest detectable viral load per minipool tested 
which is equivalent to a LOD of 30,000 IU/ml per individual donation (Lopes et al., 
unpublished data).  
3.6.2 Controls 
One negative control was included during the simultaneous extraction of all 25 minipools. 
The negative control was made up of 200 µl of normal human plasma (NHP) that was 
topped up to 1 ml with 800 µl of phosphate buffered saline (PBS). Including a negative 
control helps to monitor that no contamination occurs during the extraction and amplification 
procedure. 
MS2 bacteriophage (Roche Applied Science) is an RNA virus used as an internal control 
(IC) to validate several RT-PCR assays that detect human RNA viruses (Dreier et al., 2005). 
The stock material was diluted with PBS and carrier RNA was added to each dilution. The 
dilutions were stored at -20°C as 10-5, 10-4 and 10-3. The 10-5 dilution was used as the MS2 
working concentration which was prepared as a master mix with carrier RNA and then added 
to the samples during the extraction. The viral RNA of the IC and target HEV was then 
amplified and served as a non-competitive IC in our in-house TaqMan real-time RT-qPCR 
assay. 
3.6.3 Standards 
We used the World Health Organization (WHO) international standard (IS) for HEV RNA so 
that the HEV RNA concentrations of positive samples could be quantified. Establishing this 
IS has reduced the nucleic acid amplification technique assay variability previously observed 
in laboratories testing for HEV RNA (Baylis et al., 2012). We used the HEV WHO IS that was 
made by the Paul-Ehrlich-Institut (PEI) using plasma from a blood donor infected with HEV3 
(1st World Health Organization International Standard for Hepatitis E Virus RNA Nucleic 
Acid Amplification Techniques-Based Assays [Version 1.0]. Langen, Germany: PEI; 2011). 
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The lyophilised HEV WHO IS was reconstituted with 500 µl of nuclease free water. 
Thereafter the stock concentration of 2.5x105 IU/ml was diluted with NHP from 2.5x104 IU/ml 
to 2.5x10 IU/ml according to Table 3.2. After the dilutions were made, 200 µl of the total 300 
µl (30 µl + 270 µl) final volume was used to extract RNA from the HEV WHO standards. 
Table 3.2 Tenfold dilutions of the HEV WHO IS 
In-house Control Composition 
HEV WHO IS 2.5x105  200 μl HEV WHO IS (stock material) 
HEV WHO IS 2.5x104 30 μl HEV WHO IS 2.5x105 + 270 μl NHP 
HEV WHO IS 2.5x103 30 μl HEV WHO IS 2.5x104 + 270 μl NHP 
HEV WHO IS 2.5x102 30 μl HEV WHO IS 2.5x103 + 270 μl NHP 
HEV WHO IS 2.5x10 30 μl HEV WHO IS 2.5x102 + 270 μl NHP 
 
These dilutions were used to quantify the in-house HEV RNA positive samples namely the 
HEV PHE standards 107 – 102. After establishing the viral loads of the in-house HEV RNA 
positive samples using the HEV WHO IS, it was subsequently used as the positive control. 
The HEV PHE standards were made using of a stock concentration of 108 and NHP to make 
serial dilutions from 107 to 102 according to Table 3.3. 
Table 3.3 Tenfold dilutions of the HEV PHE standard 
In-house Control Composition 
HEV PHE Std 108 200 μl HEV PHE standard (stock material) 
HEV PHE Std 107  30 μl HEV PHE Std 108 + 270 μl NHP 
HEV PHE Std 106  30 μl HEV PHE Std 107 + 270 μl NHP 
HEV PHE Std 105  30 μl HEV PHE Std 106 + 270 μl NHP 
HEV PHE Std 104  30 μl HEV PHE Std 105 + 270 μl NHP 
HEV PHE Std 103  30 μl HEV PHE Std 104 + 270 μl NHP 
HEV PHE Std 102  30 μl HEV PHE Std 103 + 270 μl NHP 
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3.6.4 HEV RNA extraction 
All the samples were centrifuged at 3,000 rpm for 10 minutes before starting the extraction. 
The QIAamp UltraSens Virus kit (Qiagen, Germany) procedure was used to extract all the 
samples, controls and standards according to manufacturer's instructions. The purified viral 
RNA from each extract was eluted in a final volume of 65 μl and stored at -20 °C to stabilize 
the RNA until the real-time RT-qPCR was done.  
3.6.5 Principles of the in-house real-time RT-qPCR to detect HEV RNA  
An in-house HEV Taqman real-time RT-qRNA assay amplifies the ORF3 region of the HEV 
genome (Garson et al., 2012). This assay is able to quantify HEV RNA positive samples and 
has a LOD of 22 IU/ml (Hewitt et al., 2014). A dual well format was utilized to amplify the 
HEV RNA and the MS2 RNA in separate wells. Both targets were detected using labelled 
TaqMan probes unique to HEV and MS2, respectively. The HEV probe was labelled with 
FAM fluorescent dye and a minor-groove binder (MGB) modified quencher and the MS2 
probe with JOE fluorescent dye with a blackhole quencher (BHQ) (Garson et al., 2012). The 
primer sequences for HEV and MS2 amplification are shown in Table 3.5. The ABI 7900HT 
Fast PCR system (Applied Biosystems, California, USA) was used and data analysed using 
SDS software (version 2.3). The following parameters were required for a valid PCR run: A 
standard curve slope between -3 and -3.6 and an R2 value of at least 0.9 (Standard 
operating procedure for detection of Hepatitis E Virus RNA by real-time PCR. Colindale, UK: 
PHE; 2011; Hewitt et al., 2014; Andersson et al., 2015). 
3.6.5.1 In-house real-time RT-qPCR procedure 
The reaction mixture was prepared on ice using the components listed in Table 3.4. The 
sequences of primers and probes are shown in Table 3.5. Of the prepared master mix, 15 μl 
each was added to the assigned HEV and MS2 wells of the 96 well plate. 10 μl of RNA from 
each extracted sample was added to each well, thus, the total volume of each well was 25 
μl. 
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Table 3.4 Components of the master mix per reaction  
Reagent HEV Mix (n=1) MS2 Mix (n=1) 
QuantiTect Q RT-PCR master mix 12.5 µl 12.5 µl 
QuantiTect RT enzyme 0.25 µl 0.25 µl 
HEV TaqMan primer/probe mix 0.3 µl  - 
MS2 TaqMan primer/probe mix - 0.4 µl 
Nuclease free water 1.95 µl 1.85 µl 
 
Table 3.5 Primer and probe sequences for real-time RT-qPCR  
Name Sequence 
HEV Primer 1 (F) 5’- GGTGGTTTCTGGGGTGAC-3’ 
HEV Primer 2 (R) 5’- AGGGGTTGGTTGGATGAA-3’ 
HEV Probe 5’FAM-TGATTCTCAGCCCTTCGC-MGB-3’ 
MS2 Primer 1 5’- TGGCACTACCCCTCTCCG TATTCACG-3’ 
MS2 Primer 2 5’- GTACGGGCGACCCCACGATGAC-3’ 
MS2 Probe  5’-JOE- CACATCGATAGATCAAGGTGCCTACAAGC -BHQ1-3' 
*(F) = Forward primer *(R) = Reverse primer 
The plate setup shown in Table 3.6 was saved as a default setting on the software. For each 
new run, the sample type (i.e. unknown =U, standard = 107 to 102, negative = NHP or 
negative template control (NTC) = nuclease free water) and the sample name had to be 
entered in each well. All the wells marked with a “U” contained the samples that were being 
tested, in addition to this the wells containing no samples were cleared. 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
39 
 
Table 3.6 Setup of real-time RT-qPCR plate 
TaqMan 
Mix: 
HEV HEV HEV HEV HEV HEV MS2 MS2 MS2 MS2 MS2 MS2 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 107 U U U U U 107 U U U U U 
B 106 U U U U U 106 U U U U U 
C 105 U U U U U 105 U U U U U 
D 104 U U U U U 104 U U U U U 
E 103 U U U U U 103 U U U U U 
F 102 U U U U U 102 U U U U U 
G NHP U U U U U NHP U U U U U 
H NTC U U U U U NTC U U U U U 
 
The plate was sealed with an optical adhesive film and centrifuged at 3,000 rpm for 1 minute 
to remove air bubbles. The protocol was set up on the PCR machine and saved for all the 
real-time runs that were done, see cycling parameters in Table 3.7.  
Table 3.7 Real-time RT-qPCR cycling parameters 
 
3.7 Study group 2: HEV molecular testing 
A commercial qualitative TMA assay was performed in the virology laboratory of WPBTS to 
test the samples from study group 2 for HEV RNA on the Panther system (Hologic Inc., 
USA). 
 
 
PCR step Temp °C Time Cycles 
Reverse transcription 50 30 min. 1 
Initial denaturation 95 15 min. 1 
Denaturation 95 15 sec. 45 
Annealing / Elongation 60 60 sec. 45 
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3.7.1    Panther system 
The Panther automated system was used to test the individual blood donations of study 
group 2 for HEV RNA with the Procleix HEV NAT assay. The platform has a non-batch 
continuous workflow with a capacity of 120 on board that was loaded with 118 samples to 
include two assay calibrators with each batch. To validate every set of 244 samples that 
were tested the positive and negative calibrators were run in triplicate and placed in no 
particular order or position. A new set of 6 calibrators were used with each run of 250 tests. 
Reagents from each kit were scanned by the Panther system using the barcodes on each 
tube to create an inventory. The platform is divided into 6 sections; reagents bay, sample 
racks, disposable tips, multi-tube units (MTUs), universal fluids and waste (Addendum 5). 
The Panther system has a luminometer in the Mid-Bay (Addendum 5) which utilized dual 
kinetic assay (DKA) to measure the chemiluminescent signals of the target virus and IC. The 
target virus and IC have acridinium ester labelled probes emitted different light signals which 
were measured as relative light units (RLU). The dual kinetic assay (DKA) then used the 
RLU to determine if the samples tested were valid, reactive or non-reactive using the range 
shown in Addendum 6. 
3.7.2 Procleix HEV NAT assay 
The Procleix HEV assay (Grifols Diagnostic Solutions Inc., Spain) is a commercial kit that 
uses transcription-mediated amplification (TMA). The Procleix HEV NAT kits for this study, a 
collaboration between the Division of Medical Virology and WPBTS were sponsored by 
Grifols through Ilex SA. Each Procleix HEV assay kit contains 250 tests with 4 sets (total of 
1000 tests) of each reagent: an IC, target capture, amplification, enzyme, and probe and 
selection reagent. In addition, to this two calibrators were provided with the kit; an HEV 
negative control (HEPES buffered solution containing detergent, Procleix) and an HEV 
positive control (HEPES buffered solution containing detergent with an HEV RNA transcript, 
Procleix). Furthermore, the kit had the following reagents; auto detect R1 [Aqueous solution 
containing hydrogen peroxide (H2O2) and nitric acid (HNO3)] and R2 [1.6N sodium 
hydroxide (NaOH)], wash solution (HEPES buffered solution), oil (silicone oil) and DF 
[sodium bicarbonate (NaHCO3) buffered solution for deactivation fluid] which were 
developed for use on the Panther system. The kit was used to extract the individual plasma 
samples and amplify HEV RNA on the Panther system. The assay is qualitative and can 
detect all genotypes of HEV namely 1, 2, 3 and 4 with a 95% LOD of 7.89 IU/ml (6.63-9.83) 
which was determined with a HEV panel consisting of dilutions of the WHO IS (Procleix HEV 
Assay [package insert]. San Diego, CA: Hologic Inc.; 2014). Other studies were done in 
Europe, America and Australia have previously used this assay to determine the RNA 
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prevalence of HEV in their blood supply (Sauleda et al., 2015; Stramer et al., 2015; Shrestha 
et al., 2014). 
3.7.3 Principles of HEV RNA detection by TMA 
TMA is a qualitative method used by the Procleix HEV NAT assay (Grifols Diagnostic 
Solutions Inc., Spain) on the automated Panther system (Hologic Inc., USA). The TMA 
assay has the following three-step workflow: target capture, amplification and detection. 
 
 
 
Figure 3.4 Illustration of TMA (Comanor et al., 2001 with permission from Nature 
Publishing Group)  
3.7.3.1 Automated TMA procedure  
An MTU was taken from the MTU Input Queue and moved by the distributor to the sample 
dispense slot. Then the 400 µl of the wTCR, placed in the TCR carousel (rotary mixer) was 
pipetted into the MTU. Each MTU consisted of 5 single reaction tubes. Each reaction tube 
has its own disposable tip used for adding the wTCR into the tubes. Liquid level sensing was 
done before adding the sample into a reaction tube which ensured that each tube contained 
the correct volume of wTCR (400 µl). Then 500 µl of the 525 µl aspirated volume was 
dispensed into each reaction tube. After the samples were added the pipettor that did level-
sensing to check that each reaction tube contained 400 µl of wTCR plus 500 µl of sample. 
Thereafter the distributor moved the MTU to the sample mix station to mix the sample with 
the wTCR. After mixing the MTU was moved the HT incubator for target capture. During 
target capture, all the samples were treated to denature the proteins and isolate the nucleic 
acids. An internal control RNA transcript was added to the target capture reagent to monitor 
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the detection of each individual blood donation. After isolating the RNA oligonucleotides 
which correspond to the conserved regions of the HEV genome hybridized to the target HEV 
RNA present in the samples. The hybridized target in each sample was captured onto a 
magnetic particle. Once the target was captured a wash step was done to remove all the 
non-specific and unbound nucleic acids and to eliminate any potential inhibitors.  
Exponential isothermal amplification took place in a single tube. Seventy-five microliters of 
the amplification reagent which consisted of primers, nucleotides (dNTPs and NTPs) and 
cofactors and 25 µl of the enzyme reagent which contained two enzymes, the MMLV 
(Moloney Murine Leukaemia Virus) reverse transcriptase and the T7 RNA polymerase, were 
added to the tube containing the captured nucleic acids. Subsequently, the first primer 
annealed to the target RNA sequence and the RT enzyme extended the sequence and 
formed cDNA. The cDNA copy is an RNA/DNA double-stranded intermediate and the RNase 
H activity of RT enzyme was used to degrade the RNA and resulted in a single-stranded 
DNA (ssDNA). The second primer then annealed to the ssDNA and the RT enzyme 
generated a dsDNA using its DNA polymerase function. The T7 promoter region of the first 
primer was transcribed into the dsDNA sequence. Transcription was initiated by the T7 RNA 
polymerase enzyme which transcribed DNA by binding to the promoter region and 
synthesized RNA amplicons. The RNA amplicons that were formed were then used as 
templates.  
After amplifying the target RNA sequences single-stranded nucleic acid acridinium ester 
labelled probes (100 µl), which is complementary and highly specific for HEV RNA, was 
added to the reaction. Thereafter 250 µl of the selection reagent was added to the tubes to 
distinguish between the hybridized and unhybridized probes. The target and IC have 
different acridinium esters which produced different chemiluminescent signals. The IC RNA 
transcript has its own complementary acridinium labelled probe. IC-specific amplicon 
produced a rapid emission of light (termed a “flasher signal”). Whereas the amplicon specific 
to the target, HEV RNA produced a slower and longer lasting light emission (termed a 
“glower signal”). The Dual Kinetic Assay (DKA) analysed the chemiluminescent data to 
distinguish between the signals from the target virus and the IC (Procleix HEV Assay 
[package insert]. San Diego, CA: Hologic Inc.; 2014). 
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Figure 3.5 Dual kinetic assay used by the Panther system (GRIFOLS Procleix HEV 
Assay for Procleix Panther System – Operator Training Manual)   
3.8 Donor look back and notification system  
3.8.1 Follow up procedure in case of active HEV infection(s) 
Blood donors are not routinely screened for HEV infection and may have previously donated 
HEV-infected blood. Hence, we wanted to identify donors found to have active HEV 
infection. If a donor had a reactive TMA test result, the WPBTS retested the sample in 
duplicate to confirm the result. Thereafter donors that were confirmed positive were identified 
and informed of the test result by WPBTS. All unused packs from donors that tested positive 
were blocked and discarded. Therefore, no known HEV contaminated blood or blood 
products were issued to recipients. The donors with active HEV infection were offered 
counselling by the WPBTS nurse and received an informational brochure on hepatitis E. 
Furthermore the donor was also informed about of our study HEV risk questionnaire and 
requested to complete it on a voluntary basis if the donor had no objections. 
3.9 Statistical analysis 
Descriptive statistics was performed and proportions calculated to include measures of 
spread and 95% confidence intervals. We compared the HEV IgG positive and HEV IgG 
negative donors with respect to demographic factors using the chi-squared test and Fisher’s 
Stellenbosch University  https://scholar.sun.ac.za
 
 
44 
 
exact test for categorical data. All p-values were two-tailed and the significance level was set 
at 0.05. Analyses were done using Stata (version 12). 
3.9.1 Sample size 
Our sample size was based on blood donor studies were done worldwide (Table 2.2 and 
Table 2.3) to estimate the background prevalence of active HEV infection in our blood 
donations. In addition, our pilot study done in 2013 had a 25.3% HEV IgG seroprevalence 
and sample size of 300 blood donors which suggested that we need a much larger sample 
size to detect active HEV infection in our setting.  
3.9.1.1 Study group 1 
In terms of the secondary outcome of our study, to identify risk factors associated with past 
HEV infection, we recruited 250 donors of whom 140 would have been expected to have 
been exposed to pork and pork products, as a primary risk factor. To determine the 
association of pork products with HEV infection with alpha =0.05 and 80% power, we have 
used the following calculation shown in Table 3.9:  
Table 3.8 Sample size calculation for the questionnaire participants 
Pork exposure IgG Positive IgG Negative Sample size required 
140 0.6 0.5 191 
140 0.7 0.6 172 
 
3.9.1.2 Study group 2 
In terms of the primary outcome to determine the prevalence of active HEV infection in blood 
donors from the Western Cape, we had a fixed sample size of 10,000 blood donations and 
expected to identify at least 0.05% (95% CI, 0.0457-0.0543) active HEV cases, based on the 
RNA prevalence from other blood donor studies shown in Table 2.2 and 2.3.  
  
Stellenbosch University  https://scholar.sun.ac.za
 
 
45 
 
CHAPTER FOUR: RESULTS 
Two sub-studies were conducted to investigate the seroepidemiology and molecular 
prevalence of HEV infection in blood donors in the Western Cape. Study group 1 consisted 
of 250 blood donors who completed an HEV risk questionnaire and had their blood tested for 
HEV IgG antibodies and HEV RNA. Study group 2 consisted of 10,000 blood donors who 
were tested for HEV RNA, of whom only HEV RNA-positive donors were notified and asked 
to provide information on possible risk factors.  
4.1 Demographics of study participants  
The 250 blood donors were recruited at 25 randomly selected WPBTS blood donation clinics 
situated in Cape Town and its surrounding areas between September and December 2014. 
The 10,000 donors in study group 2 were from WPBTS blood donation clinics across the 
Western Cape during October and November 2015. The demographics of the two groups 
are summarized in Table 4.1.  
Table 4.1 Demographic data representing the donor profiles 
Characteristic Study group 1 Study group 2 
 N=250 (100%) N=10,000 (100%) 
Gender 
Males 
Females 
122/250 (48.8) 
128/250 (51.2) 
5,114/10,000 (51.1) 
4,886/10,000 (48.9) 
Age   
16-25 years 
26-45 years 
≥ 46 years 
  29/250 (11.6) 
  97/250 (38.8) 
124/250 (49.6) 
2,264/10,000 (22.6) 
4,160/10,000 (41.6) 
3,576/10,000 (35.8) 
Race   
Asian 
Black 
Coloured 
White 
    1/250 (0.4) 
  12/250 (4.8) 
118/250 (47.2) 
119/250 (47.6) 
     91/10,000 (0.9) 
   500/10,000 (5.0) 
3,278/10,000 (32.8) 
6,131/10,000 (61.3) 
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4.2 Study group 1: HEV serology  
4.2.1 Anti-HEV IgG seroprevalence 
Of the 250 samples that were tested for anti-HEV IgG, 106 samples (42.4%) had positive 
results. Four samples were in the grey zone with S/CO values between 0.9-1.1 on initial 
testing and were re-tested (in singlicate), yielding a positive result in each case (Table 4.2). 
Table 4.2 Retested anti-HEV IgG borderline samples 
Donor serial 
number 
1st test 
OD value 
S/CO 
value 
Initial 
Result 
2nd test 
OD value 
S/CO 
value 
Final 
Result 
23 -10599131 0.185 0.97 Grey zone 0.259 1.36 POS 
199 -10608289 0.195 1.03 Grey zone 0.448 2.36 POS 
217 -10668018 0.197 1.04 Grey zone 0.843 4.44 POS 
219 -10668030 0.193 1.02 Grey zone 0.417 2.19 POS 
*OD = Optical density *S/CO = Sample cut-off ratio                                                                                         
4.2.2 Demographics of study group 1 according to anti-HEV IgG result 
The anti-HEV IgG seroprevalence for the 250 interviewed blood donors was 42.4% 
(106/250). Figures 4.1 and 4.2 show the breakdown of the 250 donors HEV IgG result 
according to age, gender, ethnicity and area.  
 
Figure 4.1 Anti-HEV IgG seroprevalences according to age group and gender 
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Figure 4.2 Racial profiles of anti-HEV IgG for all donors  
4.2.3 Anti-HEV IgG seroprevalence according to area 
The anti-HEV IgG seropositivity rate was found to be the highest in the South Eastern 
suburbs with 51.8% (29/56) while the Southern suburbs had the lowest anti-HEV IgG 
seroprevalence with 35.1% (20/57). Donors residing in the Northern suburbs had an anti-
HEV IgG seroprevalence of 43.1% (47/109) and the Central Business District (CBD) had 
35.7% (10/28). The difference in the seroprevalences of the suburbs may be reflective of the 
population composition which varies between suburbs. Census data that is supplied by 
Statistics South Africa indicates that certain race groups are more represented than others in 
certain suburbs of Cape Town (City of Cape Town – 2011 Census Suburb Profiles, [s.a.]).  
The racial distribution of the different areas was taken into consideration when the anti-HEV 
IgG results were interpreted. A detailed representation of the donor seroprevalence is seen 
in Table 4.3, showing the number of anti-HEV IgG positive blood donors from each individual 
blood donation clinic.  
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Table 4.3 Anti-HEV IgG seroprevalences for each of the 25 blood donation clinics 
Surburb  Site of  blood 
donation clinic 
Positive anti-HEV 
IgG as (%) of total 
number recruited 
per site  
South Eastern Bonteheuwel  6  of 10 (60) 
South Eastern Belhar  1  of   8 (13) 
South Eastern Ravensmead  6  of   8 (75) 
South Eastern Athlone  4  of 10 (40) 
South Eastern Mitchells Plain  6  of 10 (60) 
South Eastern Vanguard Estate  6  of 10 (60) 
Northern Monte Vista  4  of   9 (44) 
Northern Brackenfell  2  of 13 (15) 
Northern Kenridge  5  of   9 (56) 
Northern Bellville  5  of 15 (33) 
Northern Bothasig  4  of 10 (40) 
Northern Elsies River  6  of 10 (60) 
Northern Durbanville  2  of 10 (20) 
Northern Eerste River  7  of 13 (54) 
Northern Edgemead  6  of 10 (60) 
Northern Stellenberg  6  of 10 (60) 
CBD Cape Town  5  of 13 (39) 
CBD Sea Point  2  of   5 (40) 
CBD Pinelands  3  of 10 (30) 
Southern Wynberg  1  of 10 (10) 
Southern Tokai  4  of   9 (44) 
Southern Bergvliet  6  of 10 (60) 
Southern Steenberg  0  of   8 (0) 
Southern Lansdowne  4  of 10 (40) 
Southern Plumstead  5  of 10 (50) 
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4.2.4 HEV questionnaire  
4.2.4.1 Bivariate analysis 
Bivariate analysis showed that the demographic characteristics of the donors were not 
statistically significant as regards to their risk of being HEV IgG positive (Table 4.4). 
Table 4.4 Bivariate analysis of donor demographics and anti-HEV IgG seroprevalence  
Variable Anti-HEV IgG 
positive/ Total in 
each group (%) 
Anti-HEV IgG 
negative/ Total in 
each group (%) 
p-value 
Characteristic 
Age: 16-25 
         26-45 
         ≥ 46  
6/29         (20.7) 
34/97       (35.1) 
66/124     (53.2) 
23/29       (79.3) 
63/97       (64.9) 
58/124     (46.8) 
 
Not 
determined 
(ND) 
Gender:   Male 
                Female 
57/122     (46.7) 
50/128     (39.1) 
65/122     (53.3) 
78/128     (61.0) 
0.221 
Race   :    Asian 
                Black 
                Coloured 
                White 
0/1           (0.0) 
3/12         (25.0) 
57/118     (48.3) 
46/119     (38.7) 
1/1           (100.0) 
9/12         (75.0) 
61/118     (51.7) 
73/119     (61.3) 
0.232 
Area    :   Urban 
                Semi-urban 
                Rural 
101/232   (43.5) 
5/16         (31.3) 
1/2           (50.0) 
131/232   (56.5) 
11/16       (68.8) 
1/2           (50.0) 
0.617 
 
However the following variables identified through the questionnaire were found to be 
significantly associated with HEV infection: consumption of turkey meat; consumption of 
well-done or medium to well-done organ meats; recreational canoeing; contact with rabbits 
or chickens. These variables together with non-significant variables were categorized 
according to the different possible routes of HEV transmission (Table 4.5). 
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Table 4.5 Bivariate analysis between the HEV risk factors and anti-HEV IgG status 
Variable Anti-HEV IgG 
positive / Total in 
each group (%) 
Anti-HEV IgG negative / 
Total in each group (%) 
p-value 
Foodborne and zoonotic risks 
Turkey consumption: 
Never 
1-3 times per week 
Less than once a month 
 
57/156     (36.5) 
2/10         (20.0) 
48/80       (60.0) 
 
99/156    (63.5) 
8/10        (80.0) 
32/80      (40.0) 
 
 
0.001 
Pork consumption: 
Never 
Once a week 
More than once a week 
1-3 times per week 
Less than once a month 
 
14/44       (31.8) 
18/45       (40.0) 
8/20         (40.0) 
48/94       (51.1) 
19/43       (44.2) 
 
30/44      (68.2) 
27/45      (60.0) 
12/20      (60.0) 
46/94      (48.9) 
24/43      (55.8) 
 
 
 
0.291 
Chicken consumption: 
Never 
Once a week 
More than once a week 
1-3 times per week 
Less than once a month 
 
1/2           (50.0) 
21/55       (38.2) 
80/178     (44.9) 
3/9           (33.3) 
1/2           (50.0) 
 
1/2          (50.0) 
34/55      (61.8) 
98/178    (55.1) 
6/9          (66.7) 
1/2          (50.0) 
 
 
 
0.875 
Consumption of organ 
meats prepared well-
done: 
Yes 
No 
 
 
 
57/112   (50.9) 
0/5         (0) 
 
 
 
55/112   (49.1) 
5/5         (100) 
 
 
0.026 
Consumption of organ 
meats prepared medium 
to well-done: 
Yes 
No 
 
 
 
0/5         (0) 
56/110   (50.9) 
 
 
 
5/5         (100) 
54/110   (49.1) 
 
 
0.026 
Direct contact with a 
rabbit:     
Yes 
No                    
 
 
6/25       (24.0) 
101/225 (44.9) 
 
 
19/25     (76.0) 
124/225 (55.1) 
 
 
0.045 
 
Direct contact with a 
chicken:          
Yes 
No         
 
 
3/18       (16.7) 
104/232 (44.8) 
 
 
15/18     (83.3) 
128/232 (55.2) 
 
 
0.020 
 
Waterborne risks 
Exposure to sewage 
while canoeing:   
Yes 
No 
 
 
10/38    (26.3) 
75/157  (47.8) 
 
 
28/38     (73.7) 
82/157   (52.2) 
 
 
0.017 
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4.2.4.2 Multivariate analysis 
For the multivariate analysis, we included all the variables with p-values more than 0.05 but 
less than 0.10 in a logistic regression model. The following variables were used; contact with 
a jaundiced person within past 2 years, p=0.061; beef consumption, p=0.085; and rinse raw 
vegetables before eating, p=0.097. The logistic regression analysis with odds ratios (OR), p-
values and confidence intervals (CI) is reported in Table 4.6. 
Table 4.6 Logistic regression model  
Characteristic Odds Ratio P-value 95% Confidence 
Interval [95%CI] 
Contact with a 
jaundiced person 
2.01 0.07  0.96 to 4.20 
Beef consumption 0.72 0.62  0.20 to 2.57 
Eating rinsed raw 
vegetables 
0.45 0.25  0.11 to 1.74 
 
4.3 Study group 1: HEV molecular testing 
4.3.1 HEV RNA prevalence  
 
All 25 minipools tested by HEV PCR had negative results. The pooling strategy that was 
used meant that individual samples were tested at 1:10 dilution. Therefore, if an individual 
sample would have had a low HEV viral load this could have been diluted to below the LOD 
of the pooling assay (3,000 IU/ml) and thus gone undetected.   
4.4 Study group 2: HEV molecular testing 
4.4.1 HEV RNA prevalence  
 
Of the 10,000 donor samples tested by WPBTS using the Procleix HEV NAT assay, there 
were 500 to 600 donations tested per day with approximately 25 invalid results. These 
invalid results were due to the IC RNA being too low to be detected. All samples with invalid 
ICs were retested in duplicate according to the manufacturer's instructions (Addendum 6) 
and confirmed to have a valid and non-reactive result. Overall there were 9,999 non-reactive 
(negative) samples and 1 sample with a reactive (positive) result. This, too, was retested in 
duplicate for confirmation. In addition, a plasma aliquot of the reactive donor sample was 
sent to the Division of Medical Virology for confirmatory testing using the quantitative in-
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house PCR (see above). The reactive donor was a 51 years old white male from the 
Northern suburbs. The molecular results are summarized in Table 4.7. 
 
Table 4.7 Characteristics of the HEV RNA positive donor  
 
Donor 
serial 
number 
TMA result - 
RLU 
TMA result - 
S/CO 
RT-qPCR 
result – cycle 
threshold 
(Ct) 
RT-qPCR 
result - viral 
load 
 
10840601 
 
1,879 324 
 
51.89  
 
30.7 
 
7.9x104 IU/ml  
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CHAPTER FIVE: DISCUSSION 
In order to investigate the prevalence of and risks associated with HEV infection in blood 
donors from the Western Cape, we conducted a survey and did serological and molecular 
tests. The main findings were: study group 1 had substantial evidence of past HEV infection 
but no active infection was detected among 250 participants; one active HEV infection was 
however detected among study group 2 consisting of 10,000 blood donors. This points to a 
considerable risk of acquiring HEV infection in the population of the Western Cape, here 
represented by blood donors, and an existing, albeit probably small, risk of transmission of 
undetected acute HEV infection to recipients of blood transfusions.  
5.1 Anti-HEV IgG seroprevalence of study group 1 
The total HEV seroprevalence was 42.4% with 106 of 250 blood donors positive for anti-HEV 
IgG. This is higher than the 25.3% (76/300) seroprevalence which we previously obtained for 
our pilot study (Lopes et al., unpublished data). Possible reasons for the difference in the 
seroprevalence of the current study and the pilot study is discussed in section 5.2 with 
regards to the different demographic characteristics of the blood donors. Our IgG 
seroprevalence is similar to that reported in different regions of France, which ranges from 
39.1 to 52.5% (Mansuy et al., 2015; Mansuy et al., 2011). We used the same serological test 
as Mansuy et al., i.e. the Wantai assay. Even within countries, HEV IgG seroprevalence 
rates tend to vary in spite of the same assay being used (Petrik et al., 2015). A 
seroprevalence rate exceeding 20% would classify our setting amongst the high 
seroprevalence regions and countries such as e.g. Italy with 46% (Lucarelli et al., 
unpublished) and the Netherlands with 27% (Slot et al., 2013). 
5.2 Anti-HEV IgG seroprevalence according to demographics 
The demographic profile observed in the blood donors of study group 1 were not statistically 
significant. The differences are described below, with regards to the higher seroprevalence 
associated with age, gender, ethnicity (race) and area (site of blood donation clinic). 
Age association 
In our study, there was an age-dependent effect, blood donors that were 46 years and older 
had a higher risk for past HEV infection than donors in the younger age groups. 
Furthermore, the age-dependent effect seen in this study correlates with the data from our 
pilot study (Lopes et al., unpublished data) where we observed a statistically significant 
difference in individuals that were 46 years and older (p<0.001). Another study done in 
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Nigeria showed that the HEV IgG seroprevalence increased with age and was the highest in 
participants aged 60 years and older with a significance of p=0.044 (Junaid et al., 2014). 
Previous studies in blood donors from developed countries such as Australia (Shrestha et 
al., 2014), France (Mansuy et al., 2011) and the US (Xu et al., 2013) have reported similar 
findings consistent with our results. It appears that older age is associated with an 
accumulative exposure to HEV that results in a higher anti-HEV IgG seroprevalence. In 
addition to this in Austria, Fischer et al. looked at the incidence and seroprevalence of HEV 
infection in blood donors and observed that there was a greater risk of HEV infection 
amongst donors in the older age groups i.e. 50 years and older (OR=21.62; 95%CI: 30.1-
53.3; x2: p<0.01) compared to those in the younger age groups (Fischer et al., 2015).  
Gender association 
The seroprevalence of anti-HEV IgG was similar between males 28.4% (46/162) and 
females 21.0% (29/138) from the pilot study and also between males and females in the 
current study: 45.9% (56/122) and 39.1% (50/128) respectively. In the current study 
(p=0.221) and in the pilot study (p=0.14) there was no statistically significant association 
between gender and past HEV infection. Other studies were done in blood donors from 
China (Jia et al., 2014) and France (Mansuy et al., 2011) also reported that gender was not 
a significant risk factor for HEV infection.  
Ethnic association 
Very few studies have reported on the seroprevalence of anti-HEV IgG in different race 
groups. The Western Cape, South Africa, is a unique setting with regards to its racial 
demographics: 0.3% Asian, 14.8% White, 33.9% Black and 51% Coloured people (WPBTS 
Annual Report 2013/2014, [s.a.]). As a result of the provincial demographics the WPBTS 
receives 0.9% of its blood donations from Asian people, 12.9% from Blacks, 25.4% from 
Whites and 60.8% from Coloureds (WPBTS Annual Report 2013/2014, [s.a.]). This allowed 
us to assess ethnic background as a probable risk of HEV infection. Table 5.1 shows HEV 
seroprevalences according to race group. A similar trend is seen between our current and 
the prior pilot study (Lopes et al., unpublished). 
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Table 5.1 Trend in the anti-HEV IgG seroprevalence in blood donors from the Western 
Cape 
 Anti-HEV IgG seroprevalence  
Race group 2013 - Pilot study  
N=300 
2014 – Current study 
N=250 
Black  20/100 (20%) 3/12 (25%) 
Coloured 33/100 (33%) 57/118 (48.3%) 
White 23/100 (23%) 46/119 (38.7%) 
Asian Not sampled 0/1 (0%) 
 
In the current study, we had an uneven representation of race groups: a random selection of 
blood donors were recruited irrespective of their demographics. While for the pilot study 
(Lopes et al., unpublished) we had 100 blood donors from each race group (Table 5.1). We 
observed that Coloured donors had a higher infection rate compared to White, Black and 
Asian donors. The latter pointing to possible differences in the risk of infection of race 
groups, but not a statistically significantly different in the current (p=0.232) or pilot (p=0.09) 
study. In spite of the lack of statistical significance, we believe that there may be a trend in 
evidence of past HEV infection amongst ethnic groups in the Western Cape. The provincial 
demographic profile of the Western Cape may have influenced the racial prevalence seen in 
our study.  
Area association 
Healthy individuals such as blood donors are part of the general population that are exposed 
to many potential risk factors. The differences observed in the HEV seroprevalence rate of 
the urban suburbs, could be dependent on several factors e.g. economic status, type of 
household infrastructure and community services i.e. water supply, refuse disposal etc. 
According to the census data there are some prominent differences between the above-
mentioned factors that are associated with area. For example, in a high socioeconomic area, 
such as Constantia 75.3% of the people of White ethnicity (9,380/12,452) while in a middle 
to low socioeconomic area like Athlone 2.0% of the people are White (880/45,049) (City of 
Cape Town – 2011 Census Suburb Profiles, [s.a.]).  
Donors were recruited at the blood donation clinics in the CBD are more often than not 
commuters that work in Central Cape Town. Therefore the HEV seroprevalence that we 
observed in this area was not a representative of individuals residing in the CBD. 
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Previously it was reported by Tucker et al. that people living in rural areas had a higher anti-
HEV seroprevalence than individuals from urban areas in the Western and Eastern Cape 
provinces in South Africa (Table 2.1). However, we found a high anti-HEV IgG 
seroprevalence in donors recruited from blood donations clinics in suburbs (Table 4.3). Only 
2 of the 250 donors indicated that they lived in a rural area (Table 4.4). However in France 
blood donors from a rural area, with residents that commonly hunt and eat undercooked 
meat, had a high anti-HEV IgG seroprevalence of 52.5% (Mansuy et al., 2011). These 
findings suggest that rural and urban areas may pose an equal risk of acquiring HEV 
infection. Further studies are needed to investigate the seroprevalence of anti-HEV in 
individuals that live in rural areas of the Western Cape.   
5.3 Anti-HEV IgG seroprevalence according to potential risk factors in study group 1 
We included different categories in our questionnaire to identify which means of exposure 
were associated with past HEV infection. In our study the following risk factors were 
statistically significantly associated with past HEV infection: consuming turkey or organ 
meats, exposure to surface water during recreational water sport, and having direct contact 
with rabbits or chickens. Further multivariate analysis revealed that contact with a jaundiced 
person was also a statistically significant risk factor. The risk factors associated with an 
increased risk of anti-HEV IgG seroprevalence in our study cohort were previously described 
in terms of the well-known HEV routes of transmission (Table 4.5). 
Foodborne zoonotic risks 
HEV has a foodborne zoonotic route of transmission, associated with genotype 3 which has 
been reported in South Africa (Andersson et al., 2012; Andersson et al., 2015). This 
warrants the evaluation of meat products sold in South Africa. The risk data from the current 
study found no statistically significant association with eating pork. This could be because 
we did not ask the how the questionnaire participants if they ate pork-derived products: raw, 
cooked medium to well-done or cooked well-done. An investigation was done to test for the 
presence HEV RNA in pork sausages sold at supermarkets in Italy, Czech Republic and 
Spain. The researchers found no evidence of HEV RNA in the sausage samples from Italy 
(0/128) and Czech Republic (0/92), but 6% of the sausages from Spain (6/93) were HEV 
RNA positive (Di Bartolo et al., 2012). Their findings support our assumption that pork-
derived products sold at local supermarkets may be a potential source of HEV meat 
contamination. Due to the heat resistance of HEV, it is possible that undercooked pork-
derived products could contain infectious HEV particles even after the meat is cooked in an 
oven or prepared on a fire. In our setting consuming raw or undercooked pork is not 
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common practice, however preparing meat on a fire “braai” at home or flame-grill in 
restaurants is a dietary habit in South Africa. Preparing meat on a fire does not allow one to 
set the cooking temperature to 71°C, which is required heat inactivate HEV particles. 
Therefore, this may potentially be facilitating the foodborne zoonotic transmission of HEV in 
our setting. 
As a complicating factor, a recent study (Cawthorn et al., 2013) reported that pork (37%) and 
chicken (23%) were the most substituted species found in allegedly non-pork and non-
chicken meat products sold in South African supermarkets. This could perhaps explain why 
we observed no statistical significance associated with eating pork (p=0.291) and chicken 
meat (p=0.875) amongst anti-HEV IgG positive donors (Table 4.5). Consumption of 
undercooked pig-derived meat is a major concern in the resource-rich settings; cases of 
foodborne zoonotic HEV transmission through raw or undercooked pork-derived products 
such as liver sausages (Mansuy et al., 2011; Mansuy et al., 2015). Our risk data showed that 
turkey meat which was generally less consume, but it was the only meat product that was 
statistically significantly associated with anti-HEV IgG positivity (Table 4.5). There are no 
documented cases in the literature that support the association between eating turkey and 
having past HEV infection, therefore, our finding might have been a randomly significant 
effect that requires further investigation.  
It has been reported direct contact with pigs and other HEV animal hosts (Krumbholz et al., 
2014; Lagler et al., 2014) serve as a significant risk of acquiring HEV infection. In the current 
study, we observed statistically significant association in the IgG status of individuals who 
had direct contact with rabbits (Table 4.5). Possible means of direct contact with rabbits are 
most likely due to individuals having a pet rabbit living in their backyard or visiting a petting 
zoo that has rabbits. There is evidence of HEV infection in rabbits (Geng et al., 2011; Izopet 
et al., 2012; Birke et al., 2014) however this does not explain the significant effect, which we 
found in people with more exposed to rabbits, having a lower HEV infection rate. A similar 
significance was seen in people having direct contact with chickens. Generally, farmers have 
more contact with poultry and people living in informal rural settlements that have chickens 
living in their backyards.  
Occupational risks 
We investigated possible occupational exposure to HEV and none of the variables within this 
category had statistical significance (Table 4.5). However other studies conducted in 
Madagascar (Temmam et al., 2013) and in Europe (Krumbholz et al., 2014) have found that 
having direct contact with pigs, as farmers or slaughterhouse workers, has a statistically 
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significant association with HEV infection. Verhoef et al. conducted a survey in the 
Netherlands that was similar to our study and found that working with human patients or 
working with animals were in HEV IgG positive individuals. 
Waterborne risks 
Exposure to HEV contaminated surface water is associated with transmission of HEV1 and 
HEV2. We observed there was a higher risk of infection in participants that did canoeing 
(p=0.017) as a recreational water activity. The latter could suggest that the rivers in our 
setting may be contaminated with debris containing HEV particles. The river possibly serves 
as a source of enteric pathogens including HEV, causing infection in individuals that come 
into contact with runoff from household waste, as a result of improper wastewater disposal 
(Govender et al., 2011). However, Grabow et al. reported that the seroprevalence of HEV in 
canoeists (1.8%) was found to be less than that of medical students (2.6%) who did not have 
regular exposure to contaminated water (Table 2.1). It is possible that individuals more 
exposed to possibly HEV contaminated water are at a greater risk of getting infected. 
Govender et al. have reported that water sources are polluted by unsanitary lifestyle 
practices of the residents from communities located in poor resource settings. Furthermore 
unsanitary practices can contribute to environmental pollution of water sources that 
promotes transmission of waterborne disease.  
The socioeconomic status of people living in urban suburbs may be higher than that of 
people living in poorer rural areas. Furthermore, the socioeconomic status of an individual 
affects their lifestyle, e.g. people of low economic status would generally eat chicken which 
is cheaper than   Thus our study participants may have been less exposed to surface water 
contaminated with HEV via the faecal-oral transmission. However, we cannot conclude on 
this matter until further investigations are done testing water samples for HEV contamination 
to confirm whether the waterborne transmission is a potential route of infection in our setting. 
In addition, to this sequencing should be done on HEV RNA positive samples to determine if 
HEV1 or HEV2 strains are circulating in our water sources.    
5.4 HEV RNA prevalence 
5.4.1 Study group 1 
We detected no HEV RNA reactive pools and thus no evidence of active HEV infection in 
study group 1. The fact that we found no detectable HEV RNA in study group 1 may have 
been due to the pooled testing not being sensitive enough, or there could genuinely be no 
donors positive for HEV RNA. Our pooling assay had a LOD of 3,000 IU/ml per minipool 
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which amounts to 30,000 IU/ml per individual blood donation. The Ghanaian blood donor 
study had the same pool size as ours, but their assay was more sensitive (Table 2.3). Their 
LOD was reported to be to 1000 IU/ml for the minipools and to 250 IU/ml for the individual 
donations (Meldal et al., 2013). We used the HEV WHO IS as a reference (1 IU/ml = 2.5 
copies/ml) to convert the measuring unit of the Ghanaian study’s copies/ml to IU/ml: so that 
we could compare it to our study (Baylis et al., 2013). However Medal et al. had no cases of 
active HEV infection, which suggests that the prevalence of HEV RNA in developed 
countries might be lower than we suspected in spite of the background seroprevalence data.  
Nevertheless, it seems more cost-effective to screen blood donations as minipools. Other 
advantages of using a pooling strategy include: using fewer reagents, which is beneficial in 
resource-limited settings. The turn-around time (TAT) is also reduced because more 
samples are tested in a single reaction e.g. testing a pool composed of 6 samples as one 
reaction compared to having 6 reactions for each sample. However the background 
prevalence of a setting plays a critical role in deciding whether ID- or MP-NAT would be 
more feasible. For example in a country such as South Africa which is known to be endemic 
for blood-borne viral pathogens such as hepatitis E virus (HEV) it would be ideal to have an 
assay which is sensitivity enough to test minipool. Therefore, perhaps the pool size should 
be reduced to improve the LOD. This could help to test more blood donations with reduced 
cost. However, the asymptomatic self-limiting course of HEV infection results in many 
undetected cases which are tested during the window period and can potentially infect a 
transfusion immunosuppressed recipient. 
5.4.2 Study group 2 
We detected HEV RNA in 1 of 10,000 blood donors tested, indicating a 0.01% (99%CI, 0-
0.04) prevalence of active HEV infection. Our finding is comparable to a study from the US 
(Stramer et al., 2015) with the same RNA prevalence (Table 2.2) in a larger cohort. Another 
study conducted in Spanish blood donors (Sauleda et al., 2015) had a slightly higher 
prevalence of 0.03% (Table 2.2). Nonetheless, the reactive donors in their study had VLs 
much lower than our reactive donor (Table 4.7). According to Hewitt et al. the three reactive 
Spanish donors did not have an infectious dose of HEV. A blood donation should have a VL 
4.53 IU/ml to cause HEV blood-borne transmission (Hewitt et al., 2014). This suggests that 
the blood and blood products from our reactive donor with a VL of 7.9x104 IU/ml could have 
potentially transmitted HEV via blood transfusion. 
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5.5 Summary of the main findings 
The findings of this study confirm the findings of our pilot study: there is evidence of past 
HEV infection in blood donors in the Western Cape. There appeared to be a trend with anti-
HEV IgG seroprevalence and the demographic characteristics: age, gender, race and area. 
However, this was not statistically significantly associated with a higher HEV infection rate. 
Furthermore, we found proof that blood donors may be viraemic at the time of donation and 
could be a threat to immunosuppressed blood transfusion recipients. Consequently safety of 
blood and blood products the viral load of blood donation is infectious it could reduce the.  
We found that using the HEV risk questionnaire was not a very strong predictor of infection, 
but the risk data could help to identify which blood donations have a higher chance of 
causing HEV infection. We might have found a random significant effect that was associated 
with eating turkey and being HEV IgG positive that requires further investigation. The IgG 
screening helped to evaluate to what extent HEV infection may have been undiagnosed.  
Testing for HEV RNA could be used to screen blood donations for active infection to prevent 
HEV blood borne transmission. However this would be an expensive exercise and it will 
have to be shown whether the extra expense could be justified in terms of cases of infection 
averted, especially since many recipients of blood transfusions would not suffer serious 
consequences even if they became infected with HEV. 
5.6 Study strengths and limitations 
Our study participants were prospectively recruited from WPBTS, which made sample 
collection convenient and gave us easy access to a large number of blood donations. We 
were able to test blood donors from local and provincial blood donation clinics. This allowed 
us to describe the seroprevalence, risk and RNA prevalence of HEV infection in blood 
donors from the Western Cape. In addition, to this our study was the first in Africa to report 
on the prevalence of active HEV infection in blood donors, using ID-NAT to detect HEV 
RNA.  
A limitation of our study was the sensitivity of our PCR assay, the LOD for our pools of 10 
samples was 3,000 IU/ml which would not able to detect an individual sample with a VL 
lower 30,000 IU/ml. Therefore, our assays’ sensitivity needs to be improved to be capable of 
detecting individual low positive samples in a minipool with VLs below 3,000 IU/ml. The latter 
will help to increase the negative predictive value. Another limitation was that our risk 
questionnaire was only completed by participants recruited at WPBTS blood donation clinics 
in Cape Town (study group 1) and not at all the blood donation clinics across the Western 
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Cape. Our study questionnaire may have reduced the differences in risks between the 
exposed and unexposed groups. After analysing the risk data, we observed that some 
questions could have been more specific, e.g. asking about meat preparation could be a 
better indicator of foodborne zoonotic transmission than the frequency of meat consumption. 
Furthermore to detect differences in the risks we require a greater sample size and broader 
sampling frame to recruit participants from both urban and rural areas.  
5.7 Outlook and future recommendations 
The Japanese Red Cross Society was the first blood bank to start screening blood donations 
by HEV NAT. They started screening for HEV RNA as of 2006 and are currently the only 
blood bank that has implemented HEV NAT as part of their routine blood donation tests 
(Kiely et al., 2015). Our low RNA prevalence (1 in 10,000) indicated that 0.01% of the blood 
donations could contain infectious HEV, which may cause severe liver damage in blood 
recipients. However instead of screening all the blood donations for HEV NAT, it may be 
advisable to only screen the blood and blood products given to high-risk recipients, such as 
the a renal transplant patient from the Western Cape who was diagnosed with hepatitis E 
infection (Andersson et al., 2015).  
 
An alternative approach would be serology testing to detect anti-HEV IgG positive donors 
and subsequently use their blood for high-risk recipients. The latter could be safer since 
these donors would have already cleared the HEV RNA when they test IgG positive, see 
Figure 1.4 (Kamar et al., 2012). However to find a suitable screening method for avoiding 
transfusion-transmitted HEV infections in our resource-limited setting, a cost-effectiveness 
analysis (CEA) is needed, possibly based on WHO's CHOosing Interventions that are Cost-
Effective (CHOICE) project. The WHO-CHOICE can be briefly described as a tool used to 
measure the amount of money needed, i.e. the cost of an intervention and its effectiveness, 
i.e. the number of quality-adjusted life years (QALYs) gained by implementing the 
intervention (Marseille et al., 2015).  
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CHAPTER SIX: CONCLUSION 
 
Our study found a high seroprevalence of anti-HEV IgG antibodies in the blood donor 
samples tested with a very low HEV RNA prevalence. Testing revealed a seroprevalence of 
42.4% (106/250) in this and 25.3% in the pilot study (76/300), providing evidence of past 
HEV infection in blood donors from the Western Cape. Analysis of our questionnaire 
identified that there may be an HEV contamination risk associated with meat products and 
water sources which could suggest transmission of HEV3 (foodborne, zoonotic) and HEV1 
(waterborne) occurring. As regards active HEV infection, we only found one HEV RNA 
positive donor among 10,250 donors tested, i.e.an overall HEV RNA prevalence of 0.009% 
(1/10,250). The positive case had a viral load of 7.9x104 IU/ml. At this HEV viral load, the 
transfusion-transmitted infection may have occurred in a blood recipient. The sequencing 
analysis will be done to fully characterize the HEV genotype. Previously cases of HEV3 had 
been reported from South Africa (Andersson et al., 2012; Andersson et al., 2015). We have 
shown that blood donors in Cape Town, Western Cape, have evidence of past and current 
HEV infection. Further studies are urgently needed to assess the risk factors for HEV 
infection and the risk of transmission through blood and blood products.   
The data from this study is a contribution towards a better understanding of the epidemiology 
of HEV in Southern Africa, more specifically to assessing the risk of HEV blood-borne 
transmission from blood donors from the Western Cape, South Africa. Furthermore, this is 
the first study to provide evidence for a potential risk of HEV contamination in the blood 
supply to South Africa.  
Presently blood transfusion services do not routinely screen blood donations for HEV as part 
of the serology and molecular tests. In our study, we used MP-NAT (n=250) and ID-NAT 
(n=10,000) to detect HEV RNA in the blood donations of 10,250 donors. We used both these 
NAT strategies and found that although we did not detect any active HEV donations with our 
MP-NAT, it appears to be more cost-effective than ID-NAT based on the low frequency of 1 
in 10,000 HEV RNA reactive donations. Nevertheless, because the blood donations were 
tested in real-time by WPBTS, they were able to immediately block and discard all blood and 
blood products of the one HEV reactive donor. No HEV contaminated blood was issued 
during our study. Thus to fully investigate the risk of HEV blood-borne transmission we 
would need to follow the recipients receiving blood transfusions.  
The data from this study can be used to assist policy makers in the South African blood 
transfusion services, in their decision-making on whether blood donations in our setting 
should be routinely screened for HEV infection. In addition to this, the donor risk profile from 
Stellenbosch University  https://scholar.sun.ac.za
 
 
63 
 
our study that was associated with HEV infection could be used to screen donors for risk 
factors for donating HEV contaminated blood. Based on our findings we recommend that 
MP-NAT would be more feasible as a tool to implement routine HEV screening for blood 
donations in our setting with limited resources.  
Further studies are needed to better understand the risks associated with HEV infection and 
to understand the reservoir and sources of this infection. We have shown that the risk of an 
HEV PCR positive donor, causing HEV blod-borne transmission to be low. Further studies 
may assist in identifying cost-effective means to identify those who may be HEV RNA 
positive and so further reduce the risk of on-going infection to a vulnerable population. 
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ADDENDA 
Addendum 1 – Study consent form 
PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM 
 
 
TITLE OF THE RESEARCH PROJECT: Prevalence and Risks of Hepatitis E Virus 
infection in Blood Donors from the Western Cape, South Africa 
 
REFERENCE NUMBER: S14/04/091 
 
PRINCIPAL INVESTIGATOR: Tatum Lopes 
 
ADDRESS:  Division of Medical Virology, Dept of Pathology 
                     Stellenbosch University, Faculty of Medicine and Health Sciences 
Francie van Zijl Ave, 8th Floor, 
PO Box 19063, Tygerberg Campus, 7505 
Western Cape Province 
SOUTH AFRICA 
 
CONTACT NUMBER: 021 938-9354 
 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please 
ask the study staff or doctor any questions about any part of this project that you do 
not fully understand.  It is very important that you are fully satisfied that you clearly 
understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary and you are free to decline to participate.  If you say 
no, this will not affect you negatively in any way whatsoever.  You are also free to 
withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines for 
Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines 
for Research. 
 
What is this research study all about? 
 The study will be conducted at the Division of Medical Virology, Faculty of 
Medicine and Health Sciences, Stellenbosch University in collaboration with 
Western Province Blood Transfusion Service.  
 Our project aims to identify past and active hepatitis E virus (HEV) infection in 
blood donors because we don’t know if blood donors in South Africa have active 
hepatitis E infection. Hepatitis E is an infection which is cleared by people who 
have a normal immune system. For those patients who have a very 
compromised immune system e.g. kidney transplant patients this infection can 
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lead to liver damage. We also want to find out what the risks are that are 
associated with infection with hepatitis E.  
 We will be testing around 28 000 donors for this study. The 250 blood donors 
participating in the study questionnaire will be recruited and consented over a 
period of 3 months. 
 
Why have you been invited to participate? 
 You have been asked to participate in this study because you are a blood donor.  
 
What will your responsibilities be? 
 We would like you to complete a questionnaire and we will use 2 ml of your 
donated blood for the hepatitis E tests.  
 
Will you benefit from taking part in this research? 
  This study will help us assess the potential risk of HEV transmission in blood 
and blood products. In the event that a sample is positive for active hepatitis E 
infection we will inform WPBTS who will notify you. You will be retested to 
ensure that the infection has cleared. Once your infection has cleared you will 
be able to donate blood again with no restrictions. In addition to this the 
recipient of the blood or blood products will be traced and tested. 
The long term benefit of the study is that we will be able to assess what sort of 
tests are needed if any to reduce hepatitis E transmission in South Africa and 
other endemic regions. 
 
Are there any risks involved in your taking part in this research? 
 There are no risks involved with participating in this study. 
 
If you do not agree to take part, what alternatives do you have? 
 This will not alter your blood donation or your ability to donate blood at all. 
 
Who will have access to your questionnaire? 
 Your questionnaire will not have your name on it, only your donation number. 
These questionnaires are kept confidential and are only accessed by staff 
directly involved in the study. WPTBS does not reveal the identity of the blood 
donors. If a sample is found to be positive WPBTS will contact you. 
 
 As a donor participating in this study questionnaire your research records may 
need to be inspected by the Human Research Ethics Committee (HREC). 
 
What will happen in the unlikely event of some form of injury occurring as a 
direct result of your taking part in this research study? 
 There are no risks. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
 No you will not be paid to take part in the study.  
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Is there anything else that you should know or do? 
 You can contact Dr Andersson at 082-709 6152 if you have any further queries 
or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if 
you have any concerns or complaints that have not been adequately addressed 
by your study doctor. 
 You will receive a copy of this information and consent form for your own 
records. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled (Prevalence and Risks of Hepatitis E Virus infection in 
Blood Donors from the Western Cape, South Africa). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor 
or researcher feels it is in my best interests, or if I do not follow the study 
plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 
2014. 
 
 
 
 ..............................................................   .......................................................  
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
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 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 
2014. 
 
 
 
 ..............................................................   .......................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer 
them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all his/her question satisfactorily 
answered. 
 
 
Signed at (place)......................…........……… On (date) …………....…………..2014. 
 
 
 
 ..............................................................   .......................................................  
Signature of interpreter                                     Signature of witness 
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Addendum 2 – HEV study questionnaire 
Questionnaire - hepatitis E virus infections in the Western Cape 
 
Donor serial number: ......................................       
 
1. Date of Birth:  …../….../……....  (dd/mm/yyyy)  
 
2. Gender:  M      F 
 
3. Please describe your ethnic group/culture background: 
 
 Black       White     Coloured     Other (please specify).................................. 
 
   
4. Where have you lived in the past 10 years, is the area:  
 
urban  rural    coastal, distance from sea .................. 
 
4.1 If your residential area is/was rural, please specify…………………………………………… 
 
5. Occupation: ………………………………………….. 
 
5.1 Work that involves:  
 
handling food          exposure to blood/blood products direct contact with animals 
 
 
 
 
 Name of interviewer …………………………………………. 
 
      
 
 
MEDICAL HISTORY 
 
6. Are you being treated by a doctor for a long-term illness, disorder?    
 yes    no   do not know 
If yes, specify disease………………………………………………………………………………. 
7. Are you on prescription medication? 
       yes    no   do not know 
 If yes, what medication(s) ………………………………………………………………………… 
 
8. Have you undergone surgery in the past 2 years? 
      yes    no   do not know 
 If so, for……………………………………………………………………………………………………. 
 
9. Have you had a blood transfusion (received donor blood) in the past 2 years? 
      yes    no   do not know 
  
If so, on …./…./….…… (dd/mm/yyyy)      Place:…………………………………………………........ 
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10. Have you had vaccinations / injections given in the past 2 years? 
      yes    no   do not know 
 If so, on …./…./….…… (dd/mm/yyyy)      Against…………………………………………………… 
 
11. Do you drink alcohol?     yes    no   do not know   
 
11.1 Applicable to males only, If yes do you drink 21 units or more per week?  
    
      yes      no 
 
11.2 Applicable to females only, If yes do you drink 14 units or more per week?  
    
      yes      no 
 
11.3 Do you binge drink?  
    
      yes      no 
 
11.3.1 If so, how much alcohol do you drink on average over the weekend?  
    
 ...................glasses of wine .....................beer bottles      .....................tots of spirits 
 
 
TRAVEL HISTORY 
 
12. Have you travelled outside of the Western Cape in the past 2 years? 
             yes     no   do not know 
 
Number of occasions Where ? (Place) When? (mm/yyyy) 
1.   
2.   
3.   
4.   
 
13. Have you had contact with one or more persons visiting the Western Cape in the past 2 
years? 
 yes      no   do not know 
13.1 If so, from which place? ………………………………………………………………………... 
13.2 If so, relation to the person? 
- Family member    
- Friend     
- Colleagues                 
- Others, namely ………………………  
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14. Have one or more family members/ friends/ acquaintances had jaundice in the past 10 
years? 
  yes    no   do not know 
 If so, 
Relation to patient Disease Start of disease 
1.   
2.   
3.   
4.   
 
 
FOOD CONSUMPTION 
 
15. How often do you eat in a restaurant/ fast-food outlet or have (take-out) delivered at 
home? 
 
 -More often than 1 time per week       
 - 1 time per week  
 - 1-3 times per month  
 - Less than 1 time per month  
 - Never   
  
 
16. How often do you eat one of the following products? 
Product More than 1 
time per 
week 
1 time per 
week 
1-3 times per 
month 
Less than 1 
time per 
month 
Never Do not 
know 
Beef       
Pork       
mutton       
chicken       
turkey       
wild meat       
organ meats       
Fish       
shellfish       
unpasteurized 
milk 
      
 
 
17. Before eating at home, do you normally wash the following foods with tap water? 
17.1 lettuce                      
17.2 raw vegetables         
17.3 fruit                           
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18. If you eat game products, please specify: 
Wild (which animal) Which product Welldone Half-
baked 
Raw 
     
     
     
     
 
19. If you eat organ meats, please specify: 
 
19.1 from which animal?……………………………………………………………………….... 
             19.2 from which organ?  ………………………………..……………………………………….. 
       
                 raw    half baked  welldone 
    
 
20. If you eat shellfish(eg. crab, lobster, prawns,etc.) please specify: 
        
       20.1 what kind? .............................................................................. 
 
                 raw    half baked  welldone 
 
 
21. Do you catch your own shellfish?   
        
      21.1 If not, where do you buy your shellfish? 
 
         at a supermarket  fishmonger shop (fisheries)  street vendor 
 
         restaurant, where? .................................................................................................. 
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Water consumption and contact with surface water 
 
22. How often do you consume the following type (s) of water? 
Water type Daily 1 time 
per week 
1-3 times 
per month 
Less than 
1 time per 
month 
Never Do not 
know  
Tap water 
 
      
Spring water 
(bottles) 
      
Spring water 
(pump) 
      
Water from a 
well 
      
Water from a 
river, stream 
or lake 
      
 
 
23. Do you have safe, clean ruuning tap water at home?  
 
 yes                             no  
 
24. Have you been exposed to surface water in the past 2 years? 
    
              yes     no   do not know 
 
      24.1 If so, with:  
 -ditch water  
 -recreational water  
 -sewage      
 -dirty water from stable with 
          (specify species) …………………………………………………………………………………….. 
 - otherwise, namely  …………………………… 
 
25. In the past 2 years, did you participate in any of the following recreational water 
activities? 
 
- swimming     
- sailing                                     
- canoeing     
- windsurfing/ water skiing   
- fishing                 
 
- Other?.................................................... 
 
 
Animal contact  
 
26. In the past 2 years have you had any direct contact (touch) with pigs? 
 
         yes    no   do not know 
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    26.1  If so, how often? 
  more often than 1 time per week 
  1 time per week 
  1-3 times per month 
  less than 1 time per month 
 
27. Do you live at a residence (e.g. farm) where pigs are present? 
 yes    no 
 
28. In the past 2 years have you visited a residence 
 
28.1 where pigs were present at that time?  
                        yes     no   do not know 
28.2 where animals other than pigs were present? 
   yes    no   do not know 
 
28.2.1 If so, which animal? 
…………………………………………………………………………………………………………
………………………................................................................................................................ 
 
 
29 In the past 2 years have you had direct contact with the following animals? 
Animal Category Species Yes  No Do 
not 
know 
Contact specification 
(E.g. touching, 
kissing/licking, etc.) 
Wild Deer     
 Wild boar     
 Hazen (rabbit)     
Farm animals Sheep     
 Goats     
 Oxen     
 Equine (horse)     
 Poultry (chicken)     
Pets Dog     
 Cat     
 Others………………     
 
 
30  In the past 2 years, did you prepare any foods for your pets/or other animals? 
 yes    no   do not know 
 
30.1 If yes, which foods? (please specify how it was prepared)  
...............................................................................................................................................
............................................................................................................................................... 
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Additional information and / or comments 
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Addendum 3 - Questionnaire terms and definitions 
Urban area: 
1. Most countries use a combination of total population and population density as a 
definition of urban area for statistical purposes. There are no international standard 
criteria for defining ‘urban’; however, the concept of a town with a population size 
of > 1000 is common. 
 
Some national statistical organisations define as urban areas with a locality 
threshold population of > 1000. Other countries use combined criteria of locality 
population and population density. The urban area criteria are specific to each 
country, based on their population dynamics and settlement patterns. 
 
The equivalent geographic classification for locality in the South African context is 
‘main place’. After several spatial iterations with the urban area criteria, it was 
determined that a combination of locality population and population density is 
required for the South African settlement patterns. The alternative proposed criteria 
are: 
 Main place population >=1000 (greater than or equal to 1000) and 
population density >= 500 per km² at the main place and sub-places; or 
 Main place population >=1000 and population density >= 1000 per km² 
at the main place and sub places. 
 
[Urban/rural discussion document Statistics South Africa, 2003] 
Rural area: 
1. Western Cape is using the measure of less than 150 persons per sq. km. 
www.westerncape.gov.za/.../rural-tourism-strategy-leononre-beukes.pdf 
2. If potential subsidies or institutional arrangements, such as the housing subsidy and 
the proposed land reform Settlement Grant, or the type of local authority, differ 
between 'urban' and 'rural' areas, a legal definition is required. A formal definition is 
also required to ensure consistency in data used by the different actors in rural areas. 
This issue will be given serious attention under the National Information Project. 
However, historical complexities, cultural perceptions and modem needs for service 
delivery, cannot easily be simplified into a definition that suits South African 
purposes.  
As an interim measure, we argue for a continuum of population sizes and densities 
that affect service provision. Rural areas, then, are those areas that have the 
lowest level of services, and the greatest average distance to the nearest 
service points.  
 They include large scale farming areas, much - but not all - of the ex-
bantustan areas, and small municipalities with little potential to raise 
taxes sufficient to meet the costs of services.  
 Peri-urban squatter camps, being tied to the economies of contiguous urban areas, do not 
count as rural, except in the context of sometimes being part of rural municipalities.  
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http://www.polity.org.za/polity/govdocs/rdp/rural1.html 
 
Direct contact with animals: (think in terms of risk of transmission) 
1. Touching the animal; example feeding, washing, playing or training. 
2. Coming into contact with the animals’ bodily fluids  
Saliva (being licked or bitten by the animal or being exposed to their drool) 
Blood (helping female animals give birth, nursing a wound of an injured animal) 
 
Binge drink: 
1. The National Institute on Alcohol Abuse and Alcoholism defines binge drinking as a 
pattern of drinking that brings a person's blood alcohol concentration (BAC) to 0.08 
grams percent or above. This typically happens when: 
- men consume 5 or more drinks, and when  
- women consume 4 or more drinks, in about 2 hours. 
CDC - Fact Sheets-Binge Drinking - Alcohol 
www.cdc.gov/alcohol/fact-sheets/binge-drinking.htm 
2. Binge drinking was defined as having five or more drinks on at least one occasion 
in the two weeks prior to the study. 
[ Parry CDH et al. Trends in adolescent alcohol and other drug use: findings from 
three sentinel sites in South Africa (1997–2001). Journal of Adolescence, in press.] 
 
Risky drinking (on weekdays) was defined as: for males drinking five or more drinks 
per day, and for females as drinking three or more drinks per day. From the same 
survey the corresponding rates for risky drinking during weekends was 32.8% 
(males) and 32.4% (females). 
 [South African Demographic and Health Survey. South African Department of 
Health, 1998.] 
 
3. The WHO defines binge drinking as consuming more than 60ml of alcohol per 
week where one standard drink is equivalent to 10g of pure alcohol. This means that 
consuming more than six drinks in a single sitting would be considered binge 
drinking. 
 
[(WHO) report that tracks global drinking patterns reveals that South African women 
have the biggest appetite for alcohol on the continent, with a whopping 41,2% of 
women reported to be binge drinkers.] 
http://www.destinyconnect.com/2014/05/06/do-sa-women-have-a-drinking-problem/ 
 
4. While there is no universal scientific or medical definition of what constitutes ‘binge’ 
or ‘extreme’ drinking, it usually means drinking excessive amounts of alcohol in a 
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short period of time. 
http://www.talkingalcohol.com/files/factsheets/body_bingedrinking.pdf 
 
Unrecorded alcohol consumption  
The unrecorded alcohol consumption in South Africa is estimated to be 2.2 litres pure 
alcohol per capita for population older than 15 for the years after 1995 (estimated by a group 
of key alcohol experts). [Alcohol per capita consumption, patterns of drinking and abstention 
worldwide after 1995. Appendix 2. European Addiction Research, 2001, 7(3):155–157.] 
 
 
Contact with people: (think in terms of risk of transmission) 
1. Person to person transmission  
This may occur by being in close contact with an individual or individuals for 
a long period of time or on multiple occasions for example living or working 
together which increases your risk of being exposed to pathogens that 
spread between hosts. 
- sharing eating utensils *saliva* 
- using the same bathroom 
- exposure to vomit if the person is feeling ill 
 
2. Faecal oral transmission 
This can easily take place if you share sanitary facilitates or your work 
exposes you to unclean water and direct contact with faeces. 
- Washing or cleaning a baby or elderly persons’ diaper or any person 
incapable of taking care of themselves 
- Burst sewage pipe 
Surface water: 
1. Water collecting on the ground or in a stream, river, lake, sea or ocean, as opposed 
to groundwater. 
Recreational water: 
1. Recreational water refers to all inland water which is used for recreational 
purposes. These include: 
-  full contact recreation (swimming), 
-  intermediate-contact recreation (water skiing and canoeing) and  
- non-contact recreation like picnicking and hiking alongside water 
bodies. 
 http://www.waternet.co.za/policy/g_wq.html 
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Domestic water refers to water that is used in domestic environment and also 
refers to all uses water can be put to in this environment. These include water for 
drinking, food and beverage preparation, hot water systems, bathing and 
personal hygiene, laundry and gardening. 
 
 
 
 
 
 
 
Unpasteurized milk: 
1. Milk that has not been exposed to high temperatures to destroy microorganisms and 
prevent fermentation. 
 
  
Recreational water illness: An illness that is spread by swallowing, breathing, or having 
contact with contaminated water from swimming pools, spas, hot tubs, decorative water 
fountains, lakes, rivers, or oceans. 
http://www.medterms.com/script/main/art.asp?articlekey=33192 
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Addendum 4 – WPBTS Consent Form (page 2 of 4) 
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Addendum 5 – Panther System labelled diagrams of Upper, Mid and Lower Bays 
respectively  
(GRIFOLS Procleix HEV Assay for Procleix Panther System – Operator Training) 
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Addendum 6 – Procleix HEV Assay results interpretation 
(GRIFOLS Procleix HEV Assay package insert – page 13 of 21) 
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